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Preface 
 
Pulmonary arterial hypertension (PAH) is generally defined as a sustained elevation of 
pulmonary arterial pressure without left ventricular failure. Nitric Oxide (NO) is an 
endogenously produced, locally acting gas that exerts multiple actions that help to 
maintain lung vascular function, while development of PAH is associated with reduced 
lung vascular NO bioavailability. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) 
is the critical enzyme for the degradation of endogenous NO synthase inhibitor ADMA 
to enhance NO production. Adenosine monophosphate-activated protein kinase 
(AMPK) is an enzyme that also exerts multiple actions to regulating cardiovascular 
function partially though modulating NO production. This dissertation tries to identify the 
effects of DDAH1 and AMPKα2 on hypoxia-induced PAH and the underlying molecular 
mechanisms. The findings from these studies provide new insight into the molecular 
mechanism of the development of PAH and right heart hypertrophy/failure.  
 
The dissertation has been divided into 2 chapters. The first chapter is determining 
effect of DDAH1 gene deletion on hypoxia+SU5416-induced pulmonary arterial 
hypertension and the second chapter is determining effect of AMPKα2 gene deletion on 
hypoxia+SU5416-induced pulmonary arterial hypertension. The data presented in these 
chapters are resulted from a research team in Dr. Yingjie Chen’s laboratory. I was one 
of the major contributors for these chapters where I was responsible for most areas of 
concept formation, data collection and analysis, as well as the majority of manuscript 
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composition. I will be the first author for two manuscripts to be published and these 
manuscripts are based on the data presented in these two chapters.   
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CHAPTER 1 
Effect of dimethylarginine dimethylaminohydrolase 1 (DDAH1)  
gene deletion on pulmonary arterial hypertension in mice 
 
1. Introduction 
Pulmonary arterial hypertension (PAH) is a progressive disease with a very poor 
prognosis. PAH is characterized by a progressive elevation of pulmonary arterial 
pressure, ultimately inducing right ventricular failure (1, 2). Previous studies have 
demonstrated that PAH and subsequent right ventricular hypertrophy is associated with 
diminished lung nitric oxide (NO) and cGMP bioavailability. While treatments that 
augment the NO-soluble guanylate cyclase-cGMP system have shown promise in 
attenuating PAH in animal model (3), and in human (4). However, the mortality rate for 
PAH remains extremely high (5), suggesting better understanding of biological factors 
involved in PAH development is necessary.   
 
Asymmetric dimethylarginine (ADMA) and L-NG-Monomethylarginine (L-NMMA) are 
endogenous NO synthase inhibitors that compete with L-arginine to attenuate NO 
production (6). Plasma ADMA levels are increased in experimental PAH models in 
animals (7, 8) and in patients with PAH (9), and may contribute to reduced NO 
generation observed in this disease.  ADMA is eliminated by the action of 
Dimethylarginine dimethylaminohydrolase (DDAH), which converts ADMA to L-citrulline 
and dimethylamine. ADMA is also eliminated from circulation through renal excretion 
(10). DDAH activity was reduced and negatively correlated with ADMA levels in rats with 
  2 
chronic hypoxia-induced pulmonary hypertension, suggesting DDAH deficiency may 
contribute to the increased ADMA levels and impaired NO production in PAH (7, 8).  
 
It is reported that there are two isoforms of DDAH (DDAH1 and DDAH2) that are 
encoded by two different genes (11). DDAH1 was initially identified as the enzyme 
responsible for degrading ADMA and L-NMMA (6). Recent studies have demonstrated 
that loss of function mutations in DDAH1 are associated with increased occurrence of 
coronary heart disease, thrombosis, and stroke (12, 13). DDAH2 was also reported to 
degrade ADMA and L-NMMA in vitro, similar to DDAH1 (14). It consequently was 
assumed that in vivo metabolism of NOS inhibitors would reflect the combined activity of 
both isoforms. However, we have demonstrated that DDAH1 is the essential enzyme or 
the only enzyme for ADMA degradation (6), and that DDAH1 localized specifically in 
vascular endothelium plays an important role in regulating systemic and lung ADMA (15, 
16).  
Previous studies have demonstrated that PAH is associated with decreased lung DDAH 
activity and increased ADMA levels (7, 11), but the actual impact of DDAH1 dysfunction 
in PAH development has not been examined. In addition, DDAH1 is expressed in both 
vascular endothelial cells and cardiomyocytes (17, 18), but the impact of cardiomyocyte 
DDAH1 expression in right ventricular (RV) hypertrophy that accompanies PAH is 
unknown.
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1.1. Purpose and specific aims of the study 
The purpose of this study is to investigate whether DDAH1 plays an important role in 
attenuating PAH. 
The specific aims of this study are: 
(1) To determine the overall impact of DDAH1 in PAH development and progression. 
(2) To determine the impact of cardiomyocyte DDAH1 on PAH induced RV 
hypertrophy and dysfunction. 
 
1.2. Hypotheses 
This project will test the following two hypotheses: 
• Increased systemic and lung ADMA by global DDAH1 KO will exacerbate PAH 
development.  
• Cardiomyocyte DDAH1 expression plays a protective role in RV adaptation to 
pulmonary hypertension, so that cardiomyocyte specific DDAH1 KO will 
exacerbate RV hypertrophy and dysfunction as compared to WT mice under 
equivalent levels of PAH. 
 
Overall, by using novel DDAH1 mouse strains, these studies will define the causal role 
of DDAH1 dysfunction in development of PAH and RV hypertrophy. The findings will 
help to determine whether intervention(s) to augment DDAH1 could represent a new 
therapeutic strategy for treatment of PAH and RV hypertrophy. 
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1.3. Significance of the study 
The study will explore unique new knowledge defining the causal role of DDAH1 
dysfunction in PAH development and right ventricular hypertrophy. The findings will help 
determine the therapeutic potential of increasing DDAH1 activity in protecting the lung 
against PAH development. This is important, since agents that increase DDAH1 protein 
expression have been identified, including a farnesoid X receptor agonist (INT-747) (19) 
that is currently in a Phase II clinical trial to treat primary biliary cirrhosis. Using global 
DDAH KO mice will make it possible for the first time to determine the effect of chronic 
DDAH1 dysfunction on PAH development and RV hypertrophy. Using the novel cardio-
DDAH KO mouse will help determine the impact of cardiac-specific DDAH1/ADMA/NOS 
signaling on PAH induced RV hypertrophy. 
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 2. Literature Review 
2.1. Pulmonary arterial hypertension   
PAH is a syndrome resulting from restricted blood flow through the pulmonary arterial 
circulation, resulting in increased pulmonary vascular resistance  and ultimately, right 
heart failure (20). An imbalance in the vasoconstrictor/vasodilator milieu has served as 
the basis for current medical therapies, although increasingly it is recognized that PAH 
also involves an imbalance of proliferation and apoptosis. It is now believed that the 
predominant cause of increased pulmonary vascular resistance is loss of vascular 
luminal cross sectional area due to vascular remodeling produced by excessive cell 
proliferation and reduced rates of apoptosis, while excessive vasoconstriction plays a 
significant role in approximately 20% of patients (21, 22). 
 
While a single primary cause of PAH has not been clearly identified, improved 
understanding of the disease pathways in PAH has led to therapeutic strategies, 
including the administration of prostanoids, antagonism of endothelin receptors, and 
inhibition of PDE-5. Future therapeutic options identified by basic studies include 
inhibiting pyruvate dehydrogenase kinase (PDK), the serotonin transporter (5-HTT), the 
anti-apoptotic protein survivin, several transcription factors (hypoxia inducible factor-1 
alpha, nuclear factor activating T lymphocytes), and augmenting voltage-gated 
potassium channel activity. 
 
PAH is a panvasculopathy that predominantly affects small pulmonary arteries (23). PAH 
is characterized by a variety of arterial abnormalities including intimal hyperplasia, 
medial hypertrophy, adventitial proliferation, thrombosis in situ, varying degrees of 
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inflammation, and plexiform arteriopathy. An individual patient may manifest all of these 
lesions, and the distribution of lesions may be diffuse or focal. The understanding of the 
natural history of the evolution of vascular lesions in PAH, except for patients with 
coronary heart disease, is limited because biopsies are rarely obtained in adult patients. 
However, it is believed that medial hypertrophy is an earlier and more reversible lesion 
than intimal fibrosis or plexogenic arteriopathy. 
 
RV function is a major determinant of functional capacity and prognosis in PAH (20). 
While RV hypertrophy and dilatation are initiated by increased afterload, the adequacy of 
the RV’s compensatory response is quite variable among individuals. It remains unclear 
why some RVs exhibit compensatory hypertrophy and maintain function, while others 
decompensate, exhibiting ventricular wall thinning, dilatation, and reduced RV ejection 
fraction. The neonatal RV is much more tolerant of increased PVR, partially explaining 
the better survival in children with PAH associated with coronary heart disease. RV 
function could potentially be improved by effective therapies to reduce pulmonary 
vascular obstruction or by directly improving RV contractile function. 
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2.2. Endothelial Dysfunction contributes to PAH 
In the human vascular system, the endothelium has an important role in the regulation of 
blood flow, vascular remodeling and repair. The outcome of PAH is the elevation of 
pulmonary vascular resistance mediated by vasoconstriction and obstructive cellular 
proliferation of the pulmonary vasculature. Through the synthesis and release of 
vasoactive factors, the endothelium plays a critical role in maintaining the delicate and 
precise balance between vasoconstrictor (such as endothelin-1 and thromboxane A2) 
and vasodilator (such as prostaglandin 1 and NO) in PAH. Endothelial damage and 
dysfunction disrupt this homeostasis, changing the balance to vasoconstriction. Several 
studies have suggested that dysfunction in NO signaling pathways contribute to the 
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2.3. Decreased NO bioavailability contributes to PAH  
NO in the cardiovascular and pulmonary system  
NO is a critical regulator of many biological processes. In mammalian cells, NO is 
synthesized by a family of enzymes called NO synthases, which catalyze the production 
of NO from the amino acid L-arginine (26). There are 3 known nitric oxide synthases; 
eNOS, which is an endothelial nitric oxide synthase, iNOS which is an inducible NOS, 
and nNOS which a neuronal NOS. NO has particularly important influence on the 
cardiovascular system, where it regulates vascular tone and blood pressure, platelet 
aggregation and cardiac contractility. While defects in NO synthesis exacerbate some 
diseases such as cardiovascular disease and pulmonary hypertension, excess NO 
production can also promote certain pathological conditions such as septic shock. In 
addition to important roles in the cardiovascular system, NO participates in host defense 
against foreign cells and regulates inflammation. This section will discuss the role of 
nitric oxide in regulating cardiovascular and pulmonary vascular functions, homeostasis, 
and the immune system. 
 
Physiological roles of eNOS 
NO is produced and released by the endothelium to promote smooth muscle relaxation 
(27). The main source of NO in the endothelium is eNOS, which generates NO from the 
amino acid L-arginine (28). eNOS expression and activity are stimulated by increased 
shear stress. eNOS is calcium-and calmodulin-dependent, and releases picomoles of 
nitric oxide in response to stimulation (29). Endothelial NO then diffuses into smooth 
muscle cells where it activates guanylate cyclase, which produces cyclic GMP, resulting 
in smooth muscle cell relaxation and vasodilation. In this manner, NO produced by 
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endothelial cells regulates vascular tone and blood pressure. The methylated L-arginine 
analogues ADMA and L-NMMA are inhibitors of NOS that has provided important 
information on the role of nitric oxide in biological processes. 
 
Evidence that endothelial NO plays an important homeostatic role came from studies 
using the NOS inhibitor L-NMMA or eNOS KO mice, both which showed that inhibition of 
eNOS activity causes hypertension (30). L-NMMA is a potent vasoconstrictor in vitro and 
produces a hypertensive response in animals and humans (29). In absence of vascular 
endothelium, L-NMMA has no intrinsic constrictor activity on vascular smooth muscle 
suggesting its vasoconstrictor effects are mediated by the endothelium (29). These 
findings indicate that the endothelium mediates NO dependent smooth muscle 
contractility through NOS, which is essential for the regulation of blood flow and pressure. 
In addition to regulating smooth muscle contractility, NO can regulate cardiomyocyte 
contractility through the NO/soluble guanylate cyclase/cyclic GMP dependent activation 
of PKG, which reduces cardiomyocyte contractility. This is believed to be due in part to 
PKG phosphorylation of troponin I and reduction of calcium sensitivity. NO also prolongs 
diastole, resulting in increased filling. 
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Maladaptive effects of NO in vascular system 
While NO production is important for maintaining normal vascular tone, and blood 
pressure, excessive or inappropriate release of NO can also be detrimental. A calcium-
independent isoform of nitric oxide synthase known as inducible nitric oxide synthase 
(iNOS) can be induced in vessel walls by certain cytokines and by endotoxin 
lipopolysaccharides. This induction occurs in both endothelial and smooth muscle cells, 
promoting severe vascular relaxation, hypotension and endotoxic shock. This 
pathological form of vascular relaxation is directly related to the production of NO and 
while resistant to most vasoconstrictors, it can be reversed by anti inflammatory 
treatments or inhibitors of nitric oxide synthase. 
 
Endotoxin also induces iNOS expression in venous smooth muscle (31) and in the 
myocardium and endocardium (32). Enhanced synthesis of nitric oxide by iNOS may 
therefore contribute to the venous pooling and cardiac dysfunction associated with 
endotoxemia. Furthermore, induction of iNOS under certain stress conditions is also 
associated with cardiac dysfunction (33). Therefore, in the heart as in the vasculature, 
NO may have a physiological role when generated by the constitutive enzyme that is 
normally present in the myocardium but may also exert pathological effects, such as 
dilatation and tissue damage, when generated in large quantities and for long periods by 
the inducible enzyme. 
 
Inhibitors of iNOS can reverse or prevent hypotension induced in animals by 
lipopolysaccharide, tumor necrosis factor, hemorrhagic shock or anaphylactic shock 
(29). In patients with septic shock, low dose of L-NMMA added to standard therapy 
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reversed hypotension in this condition (30). Experiments in animals indicate that a sub-
maximal level of NOS inhibition is essential for the outcome of treatment because high 
doses of NOS inhibitor lead to severe vasoconstriction, end-organ damage, and rapid 
death. This finding is not surprising in a condition such as septic shock, in which 
hypotension occurs in the presence of increased circulating concentrations of 
vasoconstrictors. One solution to this problem may be to inhibit the endogenous 
generation of nitric oxide completely while at the same time giving a nitro-vasodilator to 
reverse the hypertension and maintain vascular homeostasis (34). This treatment would 
also counteract the increased aggregation of platelets that might occur during the 
inhibition of NO synthesis (35). 
 
2.4. ADMA attenuates NO production 
NO is a vasodilator. NO also promotes endothelial cell survival and proliferation, inhibits 
excessive proliferation of vascular smooth muscle cells, and suppresses adhesion of 
platelets and inflammatory cells to the vessel wall (36). As NOS are the major source of 
NO, factors that regulate NOS activity play an important role in cardiovascular 
physiology, where NO is an important signaling molecule. NOS activity is controlled by 
several factors, including the endogenous NOS inhibitors ADMA and L-NMMA (37).  
ADMA and L-NMMA compete with L-arginine for NOS attenuating NO production. ADMA 
is a strong independent marker for cardiovascular morbidity and mortality (38). 
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Generation of ADMA  
Methylation of arginine residues in proteins by arginine methylltransferases (PRMTs) is 
the main source of ADMA (39). When the proteins are hydrolyzed, free methylarginines 
appear in the cytosol. PRMTs are distinguished as type-I and type-II. Type-I catalyze the 
formation of ADMA, whereas type-II catalyze symmetrical dimethylation of arginine to 
form Symmetric dimethylarginine (SDMA). Both types lead to formation of L-NMMA (40). 
ADMA and L-NMMA are inhibitors of NOS, but SDMA is not a NOS inhibitor (6). 
 
Type-1 PRMTs (41), are widely distributed throughout the body (42), and protein 
arginine methylation has been implicated in many processes, including RNA/protein 
interactions, transcriptional regulation, DNA repair, protein localization, protein-protein 
interaction, signal transduction and recycling or desensitization of receptors. There is 
limited evidence that elevated plasma levels of ADMA are due to increased methylation 
of arginine residues, however. Rather, plasma ADMA levels are mostly determined by 
the rate of elimination. 
 
Elimination of ADMA 
ADMA is eliminated by both renal excretion and metabolic degradation. ADMA 
metabolism is mediated by DDAH.   Since DDAH metabolizes ADMA and regulates 
plasma levels of ADMA, it can directly influence NO production by preventing ADMA 
inhibition of NOS activity (39). 
 
Humans generate approximately 300mmol of ADMA per day (approximately 60 mg) (44). 
Of this amount, approximately 50mmol/d is excreted in the urine (45). Therefore, ADMA 
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accumulates in patients with renal failure (45). Kidney transplantation normalization of 
SDMA is mediated largely by DDAH (46). Earlier studies of DDAH suggested that 
DDAH1 predominates in tissues containing neuronal NOS, whereas DDAH2 is more 
prevalent in tissues expressing endothelial NOS (47). However, more recent studies, 
using more specific antibodies and DDAH1 knockout models, have indicated that 
DDAH1 is highly expressed in tissues that express eNOS, such as the lung and 
vasculature (6). The elevation in plasma ADMA that occurs with vascular disease is 
believed to be due to impaired activity of DDAH (48). Current data indicates that ADMA 
is eliminated by both renal excretion and metabolic degradation by DDAH1, and that 
DDAH1 activity in particular, plays the predominant role in eliminating ADMA and L-
NMMA (6). 
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2.5. Protein arginine methyltransferases (PRMTs) in regulating ADMA 
production 
Protein arginine residues are methylated by a family of proteins known as PRMTs. Upon 
proteolysis of these methylated proteins ADMA and L-NMMA are released into the 
cytoplasm where they inhibit NO generation by NOS (49). To date, ten mammalian 
isoforms of the PRMT family have been identified. In mammalian cells, PRMTs have 
been classified into type I (PRMT-1. -3, -4, -6 and -8) and type II (PRMT -5, -7, and 
FBXO-11), based on their specific catalytic activity. The enzymatic activity of PRMT -2 
and PRMT -9 is unclear (50). Type-I and type-II PRMTs both catalyze the formation of L-
NMMA from L-Arginine. In a second step, type-I PRMTs produce ADMA while type-II 
PRMTs catalyze the formation of SDMA (51, 52). As with other post-translation 
modifications such as phosphorylation, arginine methylation regulates protein activity. 
Over the last 40 years, arginine methylation has been extensively studied in prokaryotes 
and eukaryotes. These efforts have established a pivotal role for arginine methylation in 
the regulation of transcription, RNA metabolism and protein-protein interactions which 
thereby influence cellular differentiation, proliferation, survival, and apoptosis (51). 
 
The catalytic activity of PRMTs is characterized by the transfer of a methyl group from S-
adenosylmethionine (SAM) to the guanidine nitrogen of arginine (52). Glycine-arginine-
rich motifs on proteins are preferential targets for methylation by the majority of PRMTs 
(53). PRTM-4 and PRMT-5 methylate arginine residues with proline-, glycine, or 
methionine-rich domain (54). Transfer of one methyl group results in the formation of 
MMA and transfer of two methyl groups can result in production of ADMA or SDMA. 
Although protein-arginine methylation has not been shown to be reversible, the Jumonji 
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domain-containing 6 protein (JMJD-6) has been shown to demethylate histone-arginine 
residues (55). In addition, prior to proteolysis, protein-incorporated MMA can be 
converted to citrulline by peptidylarginine deiminase 4 (PAD) (56). LSD-1 is potentially 
an enzyme that is capable of demethylating protein-arginine residues. LSD-1 has been 
shown to demethylate histone-lysine residues although it is unclear if it has arginine 
demethylation activity (57). PRMTs are ubiquitously expressed, however, gene-splicing 
may allow for tissue specific expression (58). Two isoforms of PRMT have been 
identified as essential for embryonic development. PRMT-1 is necessary for early post 
implantation development and PRMT-1 knock-out mice die at approximately embryonic 
day 6.5 (59). Pawlak et al. also showed that PRMT-1 is responsible for over 85% or total 
PRMT activity in embryonic stem cells. PRMT-4/CARM-1 knock-put mice die at birth and 
have disrupted estrogen-responsive gene expression (60). 
 
The activity of PRMT has been found to be regulated by binding of non-substrate 
proteins. Binding of BTG-1 and BTG-2/TIS-21 has been found to increase activity of 
PRMT-1 (61). PRMT-3 activity is inhibited by binding of the tumor suppressor DAL-1 (62). 
PRMT-1 has the ability to form homodimers and deletion of the protein domain 
facilitating dimerization results in loss of PRMT-1 enzymatic activity (63). 
 
PRMT expression levels can be altered in various disease states. Chen et al. noted 
increase levels of PRMT-1 protein in diabetic rat retina which was reversed by 
administration of telmisartan (64). This study also found that exposure of bovine retinal 
capillary endothelial cells to high glucose causes increased level of ROS production 
suggesting a possible role of ROS mediated PRMT-1 expression. Exposure of human 
umbilical vein endothelial cells (HUVECs) to fluid shear stress of > or =15 dyne/cm2 
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resulted in a two fold increase in expression of PRMT-1 mRNA via activation of the 
nuclear factor kappaB pathway (65). 
 
2.6. The critical role of DDAH1 in ADMA degradation 
DDAH plays a major role in ADMA degradation. A detailed study of the metabolic fate of 
ADMA and SDMA in rats confirmed this early idea (12). The excretion of analogous 
metabolites of ADMA and SDMA indicated a common catabolic pathway for both 
dimethylarginines. However, there appeared to be an additional pathway that specifically 
metabolized ADMA. This was demonstrated by the identification of metabolites, mainly 
citrulline, in the tissue samples and plasma of C-ADMA but not C-SDMA injected rats. 
The enzyme responsible for this specific pathway was subsequently purified from rat 
kidney and called DDAH (66), it is now known as DDAH1. 
 
The first evidence that DDAH1 regulates of the NOS pathway came from observations 
using the DDAH inhibitor, 4124W. Addition of 4124W to an isolated vascular segment 
induces a gradual vasoconstriction which is reversed by addition of L-arginine to the 
medium (67). This finding is consistent with the view that ADMA competes with arginine 
for NOS, is constantly being produced in the course of normal protein turnover and is 
degraded by DDAH1. 
 
Impairment of DDAH activity is a central mechanism by which cardiovascular risk factors 
disrupt the NOS pathway. The activity of DDAH is impaired by oxidative stress, which is 
induced by a wide range of pathological stimuli including oxidized LDL, cholesterol, 
inflammatory cytokines, hyperhomocystinemia, hyperglycemia, and infectious agents. 
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These insults inhibit DDAH activity in vitro and in vivo (68). The sensitivity of DDAH to 
oxidative stress is conferred by a critical sulfhydryl in the active site of the enzyme that is 
required for the metabolism of ADMA. The sulfhydryl can also be reversibly inhibited by 
NO in an elegant form of negative feedback (69). Homocysteine mounts an oxidative 
attack on DDAH to form a mixed disulfide, inactivating the enzyme (68). By oxidizing a 
sulfhydryl moiety essential for DDAH activity, homocysteine and other risk factors cause 
ADMA to accumulate and to suppress NOS activity. 
 
In apolipoprotein E-deficient mice, hypercholesterolemia is associated with increased 
levels of plasma ADMA and impaired angiogenesis (70). The effect of ADMA on 
angiogenesis can be reversed by administration of L-arginine. This data supports 
previous observations indicating a critical role of endothelium-derived NO in 
angiogenesis (70). The role of ADMA in modulating angiogenesis was strengthened by 
the finding that C6 glioma cells genetically engineered to overexpress DDAH resulted in 
tumors that were more vascular and grew faster than tumors from wild type cells (71). 
Expression of DDAH can also be increased by exposing endothelial cells to retinoic acid. 
The effect is associated with reduced accumulation of ADMA and increased endothelial 
cGMP levels (72). 
 
In experimental models of pulmonary hypertension, a reduction in pulmonary DDAH 
activity or expression is associated with an increase in plasma ADMA levels and 
reduced pulmonary NO synthesis. A reduction in DDAH activity could explain elevated 
plasma ADMA levels and L-arginine responsiveness in patients with pulmonary 
hypertension (73). These above studies indicate that DDAH and plasma ADMA levels 
are important for the regulation of NO synthesis. 
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Global DDAH1 deletion accumulated ADMA and loss of homeostasis 
Hu et al (6) provided strong evidence that DDAH1, rather than DDAH2 is largely 
responsible for the degradation of ADMA. Our group generated a murine model of global 
DDAH1 knockout (DDAH1-/-) by targeting exon 4 of the DDAH1 gene. The DDAH1-/- 
mice displayed normal developmental features while showing negligible DDAH activity in 
kidney, brain, and lung tissues. The abrogation of DDAH enzymatic activity was 
surprising because expression of the DDAH2 was unaffected. The expression of 
endothelial NOS, protein arginine methyltransferases 1 and 3, and cationic transporter 
were also unaffected. With the loss of DDAH activity there were significant elevations in 
tissue and plasma ADMA and L-NMMA. 
 
In support of a role for DDAH1 in regulating endothelial function, isolated aortic rings 
from the DDAH1-/- mice manifested impaired endothelium dependent vasodilation in 
response to acetylcholine, consistent with ADMA induced suppression of NOS. These 
animals also exhibited a significant increase in blood pressure that was reversed by 
infusion of L-arginine, consistent with the competitive inhibition of NOS by ADMA (6). 
Most importantly, tissues obtained from DDAH1 KO mice are unable to degrade ADMA 
and L-NMMA even the DDAH2 protein expression in these tissues are unaffected (6), 
indicating that DDAH1 is essential for ADMA and L-NMMA degradation. Consistent with 
the critical role of DDAH1 in ADMA degradation, ADMA content was not affected by 
selective DDAH2 gene silencing in cultured cells or in vivo (6).  
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ADMA plays an important role in the regulation of vascular tone by acting as an 
endogenous inhibitor of NO synthesis. By inhibiting NO synthesis, plasma ADMA may 
reduce vascular compliance, increase vascular resistance, and limit blood flow. 
Furthermore, plasma ADMA may promote atherogenesis as it opposes the 
vasoprotective effects of NO. Thus, elevations in plasma ADMA may accelerate the 
progression of atherosclerosis and increase the risk of cardiovascular events. 
 
In summary, DDAH1 is essential for degradation of endogenous NOS inhibitor ADMA, 
and is thus a critical regulator of endothelial NO production. DDAH1 reduces blood 
pressure, and would be anticipated to reduce adverse cardiovascular outcomes, 
particularly in diseases such as pulmonary hypertension where vascular resistance is a 
primary cause and increased ADMA levels are a defined risk factor. The research is 
therefore designed to determine the role of DDAH1 in development and progression of 
PAH and subsequent right ventricular heart failure. 
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2.7. SU5416 in PAH model generation 
Vascular endothelial growth factor (VEGF) is abundantly expressed in the normal lung 
(74) and has a prosurvival and antiapoptotic role in endothelial cells (EC). SU5416, 3-
(3,5-dimethyl-aH-pyrrol-2ylmethylene)-1, 3-dihydroindol-2-one  is a selective and potent 
small molecule inhibitor of the VEGF Receptor 2 (VEGFR2) tyrosine kinase.  It has been 
shown to inhibit VEGF dependent EC proliferation in vitro and in animal models (75, 76), 
has shown broad in vivo antitumor activity (77) and was the first VEGFR 2 inhibitor to 
enter clinical development for cancer therapy. Utilized to inhibit tumor growth by limiting 
angiogenesis, SU5416 was well tolerated, and showed initially promising results in 
phase I trials in patients with terminal cancers (78). However, expanded phase III trials 
did not find a statistically significant clinical benefit, and further development of this drug 
for clinical purposes was discontinued. Nevertheless, SU5416 has continued to be used 
in research as a way to perturb endothelial cell growth. 
 
Kasahara et al. (79) developed a rodent model of inflammation independent emphysema 
based on VEGF receptor blockade. This model provides an alternative explanation for 
emphysema based on the hypothesis that a failure of the lung VEGF receptor signaling 
may significantly contribute to the unique characteristics of pulmonary emphysema (79). 
Evidence that lung airspace enlargement in newborn mice treated with a soluble VEGF 
receptor (80) or lung specific deletion of VEGF using Cre-Lox approach (84) support the 
data obtained with this model (79). The role of apoptosis in the lung damage observed in 
emphysema is increasingly being recognized. Emphysema triggered by the VEGF 
receptor blocker SU5416, which is characterized by the presence of apoptotic alveolar 
septal cells, is prevented by a broad spectrum caspase inhibitor (79). Moreover, Tuder et 
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al. (82) demonstrated that a superoxide dismutase mimetic protects against the 
development of apoptosis and emphysema induced by SU5416 thus suggesting that 
VEGF receptor blockade triggers lung oxidative stress, which is causally involved in 
alveolar septal cell death in this emphysema model. 
 
A decade ago, Taraseviciene-Stewart et al. (83) showed that VEGF receptor blockade 
with the VEGFR-1/VEGFR-2 antagonist SU5416 combined with chronic hypoxia resulted 
in severe angioproliferative pulmonary arterial hypertension (PAH) with neointimal 
changes in adult rats. Although classic animal models of pulmonary hypertension (that is, 
the monocrotaline and hypoxic models) do not form obstructive intimal lesions in the 
peripheral pulmonary arteries, the SU5416 models has shown pulmonary arterial 
changes resembling plexiform lesions. Moreover, a recent report clearly demonstrates 
that severe pulmonary hypertension in a very late stage of the 
SU5416/hypoxia/normoxia exposed rat is accompanied by the formation of plexiform like 
lesions that are indistinguishable from the pulmonary arteriopathy of human pulmonary 
arterial hypertension (84). The finding that SU5416 promotes plexiform lesions, which is 
a endothelial hyperproliferative disorder is rather surprising, given that this drug inhibits 
endothelial cell growth and angiogenesis. However, as described below, the suspected 
mechanism SU5416 induced plexiform lesions makes this drug highly useful for 
understanding pathology and treatment of PAH. (85-89).  
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The SU5416 model and rodent models of PAH 
Tuder et al. (90) demonstrated immunohistochemically and via in situ hybridization that 
the EC in the plexiform lesions, not in the normal vasculature, express mRNA and 
protein for VEGF (the survival factor for EC) and VEGFR-2, thus suggesting that the 
formation of these lesions in PAH involves a process of disordered angiogenesis. 
Moreover, in PAH, the population of lung EC expands in a monoclonal pattern (91), and 
these EC contain an inactivating mutation of the transforming growth factor receptor II 
(92). Therefore, Taraseviciene-Stewart et al. (83) postulated that the occlusive 
neointimal lesions increase from a process of dysregulated angiogenesis that has 
several features in common with that seen in neoplastic processes. They used SU5416 
to treat the rodent model of mild to moderate pulmonary hypertension under the chronic 
hypoxia. The results unexpectedly showed that in chronically hypoxic rats, SU5416 
causes pulmonary arterial EC death, followed by obliteration of the precapillary arterial 
lumen by the proliferating EC, which is associated with a severe, irreversible PAH (83). 
Moreover, the effect of the VEGF receptor blockade could be reversed by inhibitors of 
apoptosis, suggesting that increased apoptosis of EC in response to the loss of survival 
signaling creates conditions favoring the emergence of apoptosis resistant cells with 
increased growth potential. Importantly, in this model, it was shown that chronic hypoxia 
plus VEGF receptor blockade caused severe pulmonary hypertension, which persisted, 
and even progressed, after the animals were no longer being subjected to the hypoxic 
stimulus. Moreover, the defining pulmonary vascular alteration, arterial occlusion by 
proliferating ECs, was not reversible upon re-exposure to normoxia and removal of 
SU5416 (83). 
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This model of severe PAH was therefore considered to be useful for better addressing 
the etiological mechanisms involved in the hyperproliferation of EC that characterizes 
the plexiform lesions of human PAH (83, 84). 
 
In contrast to the SU5416 model, other classical rodent models of mild to moderate 
pulmonary hypertension, (i.e. the chronic hypoxia and monocrotaline models) lack 
clustered proliferating EC in the lumen of the pulmonary arteries (93, 94). In these 
models, the defining pulmonary vascular alteration, medial muscular thickening of the 
proliferating SMC, is potentially reversible upon re-exposure to normoxia or with the 
passage of time after monocrotaline injection (93, 95, 96). Together, these rat models 
offer the perspective that medial muscular thickening due to proliferating SMC may be 
reversible, while arterial occlusion by proliferating EC appears to be irreversible (97). 
 
Together, the literature suggests that the pathological features of the SU5416 PAH 
model is currently the most appropriate small animal model available for investigating 
development and treatment of PAH.  
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 3. Meterials and Methods 
The central aim of the study is to test the hypothesis that DDAH1 plays an important role 
in attenuating PAH through degrading ADMA. We have engineered novel global DDAH1 
knockout (global DDAH1 KO) mice (6, 98), and cardiomyocyte specific DDAH1 knockout 
mice (cardio DDAH1 KO) mice to study the effects of DDAH1 on PAH and RV 
hypertrophy. 
 
3.1. Experimental Animals 
We used C57BL mice, global DDAH1 KO mice, and cardio DDAH KO mice as control 
and hypoxia+SU5416 groups. C57BL mice are one of the most widely used inbred 
strains. Mice were housed in a temperature-controlled (20ºC ± 2ºC) environment with a 
12-h light-dark cycle, and free access to water and mouse chow provided after weaning 
at 18 days of age. The Animal Care and Use Program at the University of Minnesota, 
maintains full accreditation from the Association for Assessment and Accreditation of 
Laboratory Animal Care, International (AAALAC) and complied with the US Animal 
Welfare Regulations, the National Research Council (NRC) Guide for the Care and Use 
of Laboratory Animals, and Public Health Service Policy on the Humane Care and Use 
of Laboratory Animals. The University of Minnesota has an Animal welfare Assurance on 
file with the National Institutes of Health’s Office of Laboratory Animals Welfare (NIH-
OLAW). Training for all personnel involved in animal care is required. 
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Genotyping Global DDAH1 KO mice 
Global DDAH1 KO mice were engineered in our lab by crossing DDAH1flox/flox mice (15) 
with protamine (Prm)-cre mice (129-Tg(prm-cre)58Og/J, Jackson Laboratory) as we 
previously reported (6). The DDAH1 gene was deleted in the sperm of the male double 
heterozygote Prm-cre/DDAH1 flox/+ mice. When these male mice were crossed with 
wild type female breeders, DDAH+/- mice were generated. The homozygote global 
DDAH1-/- was generated by inbreeding of the heterozygotes. Polymerase chain reaction 
was performed for genotyping of the offspring using primer pairs 5’-AAT CTG CAC AGA 
AGG CCC TCA A-3’ and 5’-GGA GGA TCC ATT GTT ACA AGC CCT TAA CGC-3’ for 
the wild type allele and 5’-TGC AGG TCG AGG GAC CTA ATA ACT-3’ and 5’-AAC CAC 
ACT GCT CGA TGA AGT TCC-3’ for the knockout (KO) allele. 
 
Generation of Cardio-DDAH1 KO mice 
Our lab also generated an inducible cardiomyocyte specific DDAH1 KO strain by using 
the strategy described in Figure 1. Briefly, adult α-MHCMerCreMer mice, which express a 
tamoxifen inducible Cre specifically in cardiomyocytes, were crossed with DDAH1flox/flox 
mice to generate DDAH1flox/flox/α-MHCMerCreMer. DDAH1flox/flox mice were used as controls, 
and are designated as WT for convenience. DDAH1flox/flox/α-MHCMerCreMer mice have 
normal cardiac structure and function during unstressed conditions as compared with 
either DDAH1flox/flox or α-MHCMerCreMer mice. DDAH1flox/flox/α-MHCMerCreMer and DDAH1flox/flox 
were given 4-hydroxytamoxifen (4-HOT, Sigma) in peanut oil at 20mg/kg per day for 12 
injections (i.p.). 
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Cardio-DDAH1 KO  Control (WT) 
4-HOT  i.p.   
 
 Structural and functional tests  
>6 weeks after the last 4-HOT  
injection 
 
DDAH1flox/flox/ α-MHCMerCreMer  
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3.2. Experimental protocols and procedure 
Global DDAH1 KO, Cardio DDAH1 KO, and C57BL mice were exposed to 2 different 
conditions as described in Table 1 below. For Sugen 5416 (SU5416) treated mice, the 
mice in the hypoxia group received subcutaneous weekly injection of SU5416 (25mg/kg, 
R&D System). Sham group was given vehicle injections. For hypoxia treatment, mice 
were gradually acclimatized in a hypobaric chamber to hypoxia for 1 week and then 
maintained at a simulated altitude of 18,500 feet (10% oxygen) for 2 more weeks (figure 
2). The chamber was opened once every week for cleaning, feeding, and injection. 
Animals were monitored daily by our investigators including weekends. After hypoxic 
exposure for a total of 3 weeks, determination of RV pressure and hypertrophy was 
performed as described. The mice in the sham group were kept in normobaric conditions 
for 3 weeks, followed by determination of RV pressure. Heart and lung from all 
experimental groups were then quickly extracted, weighed, snap frozen in liquid nitrogen 
and stored at -80ºC until analyses. 
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Figure 2. Protocol for hypoxia+SU5416-induced pulmonary arterial hypertension 
 
Table1. Experimental groups. 
 A. Sham B. Hypoxia + Sugen 5416 
Aim-1 1. Wild type 
2. Global DDAH1 KO 
3. Wild type 
4. Global DDAH1 KO 
Aim-2 5. Wild type 
6. Cardio-DDAH1 KO 
7. Wild type 
8. Cardio-DDAH1 KO 
 
Sugen 5416  was given at a dose of 25mg/kg/week in each mouse (for Group-B). 
The hypoxia (Group-A) was given vehicle injections. N=12 each group. 
 
Weeks













1st week 2nd week 3rd week SU5416 SU5416 
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3.3. Measurements 
Right ventricle catheterization 
RV pressure was determined with a 1.2F pressure transducer. RV systolic pressure, RV 
diastolic pressure, RV dP/dt max and negative dP/dt min were determined during 
continued anesthesia (15, 99, 100, 101). Mice were first anesthetized with 2% 
isoflurance and intubated with 20-gauge Teflon tube attached to MiniVent type 845 
mouse ventilator (Hugo Sachs Elektronik). A 1.2F pressure catheter (Scisense Inc., 
Ontario Canada) was introduced through the right common carotid artery into the 
ascending aorta for measurement of systolic and diastolic blood pressures as described 
previously (99, 100). For RV hemodynamics, open-chest RV catheterization was 
performed during anesthesia with 2% isoflurane. Data were collected when steady state 
was reached (102). The catheter was then advanced into the pulmonary artery for 
measurement of pressures.  
 
Sample preparation for ADMA and L-NMMA measurement 
After the final hemodynamic assessment, the mice were euthanized by exsanguination, 
and heart, lung, and other major organs were flushed with flushed with PBS and 
harvested. Lung weight was determined and the left lung was snap-frozen in liquid 
nitrogen for biochemical analysis. The airways of the top right lobe were perfused with 
PBS and then fixed in 10% buffered formalin for histological analysis. The blood samples 
were collected for plasma levels of ADMA, L-arginine, and L-NMMA. The wet weight of 
RV and of left ventricle (LV) + septum (S) was weighed and the ratio of RV weight to 
LV+S was calculated as an index of RV hypertrophy (102, 103, 104). 
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Tissue Homogenization for Western Blots 
Lung tissue was minced into fine pieces, weighed and suspended (26:1 v/w) in ice-cold 
complete lysis buffer A (pH=7.4) comprised of the following: 10 mM HEPES, 350mM 
NaCl, 20% glycerol, 1% Igepal-CA630, 1mM MgCl2, 0.1 mM DTT, 0.1mM EGTA, and 
protease inhibitor cocktail (Roche Applied Science). Each lung was homogenized in a 
PowerGen homogenizer (Fisher Scientific; Waltham, MA) at 4oC. The homogenates 
were first centrifuged (4oC) for 10 min at 3,000g, and supernatant was separated from 
the pellet. The supernatant was centrifuged (4oC) for 15 min at 10,000g to obtain the 
soluble fraction. The nuclear fraction was isolated using this pellet re-suspended by 
complete lysis buffer B containing the following: 20 mM HEPES, 350 mM NaCl, 10% 
glycerol, 1 mM MgCl2, 0.1 mM DTT, and protease inhibitor cocktail (Roche Applied 
Science) and centrifuged again for 30 min at 12,000g. The supernatant of this fraction 
contains nuclei. Protein concentration was measured using Spectronic Genesys 5 
spectrophotometer (Milton Roy) at 562 nm absorbance. 
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Procedure for Western Blots 
Protein levels were measured by Western blot analysis. Separating gel (375 mM Tris-
HCl; pH=8.8, 0.4% sodium dodecyl sulfate (SDS); 10% acrylamide) and stacking gel 
(125 mM Tris-HCl; pH=6.8; 0.4% SDS; 10% acrylamide monomer) solutions were made, 
and polymerization then was initiated by N,N,N’,N’– teramethylethylene diamine 
(TEMED) and ammonium persulfate (APS). Separating and stacking gels were then 
quickly poured into a gel-box (Hoefer Inc, Holliston, MA). Twenty μg of protein from lung 
homogenates in sample buffer (100 mM Tris-HCl, pH=6.8, 2% SDS, 30 mM dithiothreitol, 
25% glycerol) was then loaded into the wells of the 10% SDS-PAGE gels, and 
electrophoresed at 40V for overnight. The gels were then transferred at 60V for 6 hours 
onto a nitrocellulose membrane (Bio-Rad, Hercules, CA). Membranes were blocked in 
3% nonfat milk in PBS with 0.1% Tween-20 for 1 hour. After blocking, membranes were 
incubated in 5% bovine serum albumin (BSA) at 4oC overnight with the appropriate 
primary antibodies: eNOS (1:1000, BD Biosiences), DDAH-1 (1:800,Lifespan 
Biosciences), DDAH-2 (1:800, Santa Cruz Biotechnology), CAT (1:1000, Santa Cruz 
Biotechnology), PRMT-1(1:1000, Santa Cruz Biotechnology), and PRMT3 (1:600, 
Sigma-Aldrich). Following three washes in PBS with 0.4% Tween-20, membranes were 
incubated with horseradish peroxidase- conjugated secondary antibodies in 3% nonfat 
milk at room temperature for 120 min. Following three washes in PBS with 0.4% Tween-
20, an enhanced chemiluminescence (ECL) detection system (Amersham, Piscataway, 
NJ) was used for visualization. Densitometry and quantification were performed using a 
Kodak film cartridge, a scanner interfaced with a microcimpter, and the NIH Image J 
Analysis software program. To ensure equal loading of protein, Ponceau-S-staining was 
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performed for each membrane. Membranes were stripped and reprobed for B-actin 
(1:500, Sigma) and Vinculin (1:1000, Santa Cruz Biotechnology) as loading controls. 
 
Determination of tissue ADMA, L-NMMA, SDMA, and L-arginine 
Lung ADMA, L-NMMA, SDMA, and L-arginine levels were determined using a high-
through put liquid chromatographic-tandem mass spectrometric method (6, 15, 105).  
Briefly, For ADMA, bromcyan-agarose (0.4g) was suspended in 10 ml of 1 mM HCl in 
methanol and incubated for 30 min at room temperature. After incubation, the mixture 
was filtered and washed five times with 5 ml of 1 mM HCl and 5 ml of water. To prepare 
a copper-ornithine-complex, 0.125 g was dissolved in 1.25 ml of water. Small amounts of 
CuCo3 were added until a blue color was obtained. After filtration of the solution the 
filtrate was brought to pH 10 with 10 M KOH. The washed bromcyan agarose was 
suspended in 1.25 ml of the copper ornithine complex and was shaken overnight at 4 oC. 
The next day the suspension was filtered and washed one time with 1 M HCl and ten 
times with 10 ml water. The ornithine bromcyan agarose was then suspended in a 20 % 
solution of dimethylamine in water and stirred for 24h at 50oC. The suspension was 
filtered and washed two times with 10 ml of water. The filtrate together with the washings 
was concentrated to dryness in a vacuum to remove any remaining dimethylamine. The 
residue was dissolved in water again and concentrated to dryness in vacuum for a 
second time. The final residue was dissolved in water to yield a stock solution which was 
stored at -20 oC. 
 
 Arginine levels were analyzed as described for ADMA with the following modifications: 
[13C5] ornithine HCl was used instead of [2H6] ornithine HCl to prepare the copper 
  33 
ornithine complex, and the ornithine bromcyan agarose was suspended in a 20 wt.% 
solution of dimethylamine. Purity and identify of ADMA was assessed by HPLC and LC-
MS. Briefly, fluorescenece (RF2000 fluorescence detector, Dionex, Germering, 
Germany) was detected as previously described after solid phase extraction (SPE) with 
carboxylic acid (CBA) cartridges, online o-phthaldehyde (OPA) derivatisation, and 
separation on a phenyl column from Macherey-Nagel (Duren, Germany), at excitation 
and emission wavelengths of 340 and 453 nm, respectively, Mass spectra were 
generated by direct injection without prior chromatography. 
Lung DDAH activity was determined as previously described (6, 105). 
Briefly, Lung tissue samples (20 mg frozen tissue per determination of DDAH activity 
from a single organ) were homogenized in PBS buffer with protease inhibitor as 
described above to minimize possible interference by endogenously released ADMA. 
The homogenate was centrifuged in a pre-cooled (4oC) centrifuge for 5 min at 12,000 × 
g. For the DDAH activity assay 50 µl aliquots of the resulting supernatant were added to 
50 µl aliquots of PBS buffer containing 20 µM ADMA and incubated for 60 min at 37oC. 
Reactions were stopped and ADMA was determined as described above. Enzyme 
activity was calculated as follows using an incubation time of 60 min. 
 
Quantification unlabeled and stable-isotope labeled L-arginine, ADMA and SDMA was 
performed  by LC-tandem MS by a modification. All compounds were analyzed as their 
butyl ester derivatives. Derivatization was performed in 96 well u shaped 96 well 
polypropylene plates. After addition of 100 µl of 1 M HCl in 1-butanol, plates were sealed 
with aluminum foil and u shaped 96 well polyprophlene plates were heated at 65o C on a 
96 well aluminum block for 30 min. For evaporation, aluminum seal was removed and 
open plates were heated at 85 oC for 30 min. After evaporation of the derivatization 
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reagent, samples were reconstituted in 100 µl aliquots of methanol water, 50:50 (v/v) 
containing 0.1 wt.% ammonium formate, pH 4. The pH was adjusted with formic acid. 
Afterwards, polypropylene plates were transferred to an autosampler (HCS CombiPAL, 
CTC Analytics, Switzerland), and 10 µl aliquots were injected onto the chromatographic 
column for each sample. 
 
LC- tandem MS analyses were performed on a Varian (Palo Alto, CA, USA) 1200L Triple 
Quadrupole MS equipped with two Varian ProStar model 210 HPLC pumps. Separation 
of analytes from major matrix was achieved with a Chirobiotic T (20mm × 1.0 mm i.d.) 
microbore guard column packed with teicoplanin covalently bonded to 5 µm particle size 
spherical silica. Acetonitrile containing 0.1 wt.% ammonium formate water containing 0.1 
wt.% ammonium formate, pH 4 (60:40 v/v), served as isocratic eluent at 28oC, with a 
flow rate of 0.2 ml/min. Nitrogen was used as the nebulzing and drying gas (380oC) at 90 
and 180l/h, respectively, For ionization in the positive electrospray ionization (ESI+) 
mode the needle and shield voltage were set at 5600 and 400 V, respectively. 
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Histological analysis 
Comprehensive histological analysis was performed to determine pulmonary vessel 
muscularization, fibrosis, and cardiac hypertrophy.  
 
Sample preparation for histological staining 
Sample cross-sections were cut (5 μm thick) from the middle portion of lung tissues in a 
microtome (Leica Biosystems, Buffalo Grove, IL), placed on slides in tissue float bath at 
40oC , and incubated overnight at 37oC. The sections were deparaffinized as following 
steps before stained; 1) Immerse slides in xylene for 5 min. 2) repeat once in fresh 
xylene for 5 min. 3) immerse slides in 100% ethanol for 5 min in two times. 4) immerse 
slides in 95% ethanol for 5 min in two times. 5) immerse slides in 70% ethanol for 5 min 
in two times. 6) immerse slide in 1X PBS for 5 min. 
 
Determination of lung vascular muscularization 
For the relative muscularization of pulmonary arterioles, the cross-sections were stained 
with Hematoxylin, Mayer’s (Lillie’s modification) and incubated for 5 minutes. 
Hematoxylin stains a bluish-purple color for smooth muscle cell and mitochondria, while 
nuclei stain dark blue. Stained sections were rinsed in 2 changes of distilled water to 
remove excess stain and Eosin Y solution (Modified Alcoholic) were applied for 3 min. 
Stained sections were rinsed in 3 changes of absolute alcohol before mounting with 
Vectamount medium (Vector Laboratories). Lung artery muscularization images were 
visualized and captured using a Zeiss Axio-series microscope and software at a 
magnitude of 20X. Briefly, in each mouse, 60 intra-acinar arteries (50-200 μm) were 
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examined and categorized as nonmuscular (NM), partially muscular (PM) or fully 
muscular (FM). The relative percentage of NM, PM, and FM arteries were calculated (99, 
100, 102).  
 
Determination of lung fibrosis 
For Lung fibrosis, the tissue sections were stained using Masson’s Trichrome Stain Kit 
from Scy Tek Laboratories. Briefly, the sections were placed in preheated Bouin’s Fluid 
in a water bath at 56 O – 64O C in a fume hood and then placed in preheated Bouin’s 
Fluid for 60 min followed by a 10 min cooling period. The slides were rinsed in tap water 
until sections were completely clear and then equal parts of Weigert’s (A) and Weigert’s 
(B) were applied and the slides were stained with working Weigert’s Iron Hematoxylin for 
5 min. The sections were rinsed in running tap water for 2 min and Biebrich Scarlet/Acid 
Fuchsin Solution was applied to the slides for 15 min and then rinsed in distilled water. 
The sections were differentiated in Phosphomolybdic/Phosphotungstic Acid Solution for 
15 min until the red collagen stain is visible. Without rinsing, Aniline Blue Solution was 
applied to sections for 10 min and then rinsed in distilled water. Finally, Acetic Acid 
Solution (1%) was applied for 5 min and then dehydrated in 2 changes of 95% Alcohol, 
followed by 2 changes of Absolute Alcohol. Percentage tissue fibrosis was calculated as 
previously described (99, 102, 106, 107). 
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Measurement of right ventricular fibrosis and cardiac myocyte hypertrophy 
Tissue sections from the central portion of the RV were stained with Sirius Red (Sigma) 
for detection of fibrosis, and FITC-conjugated wheat germ agglutinin (AF488, Invitrogen) 
to assist in the evaluation of cardiac myocyte size.  
 
Sirius Red staining 
Sirius Red staining was performed as follows; 1) Stain in pico Sirius red for one hour. 2) 
Rinse in two changes of acidified water. 3) Remove most of the water from the slides by 
vigorous shaking or blotting with damp filter paper. 4) Dehydrate in three changes of 
100% ethanol.  
 
Wheat Germ Agglutinin (WGA) staining 
For wheat germ agglutinin (WGA) staining, deparaffinized slides were incubated for 1 
hour at room temperature with primary antibody against WGA conjugated to FITC (50 
µg/ml) in PBS. Slides were washed 3 times in PBS, mounted in Vectashield with DAPI 
(Vector Labs) and imaged by fluorescence microscopy. The cross sectional area of at 
least 120 cells/sample (from 5 areas) and at least 4 samples of each group were 
averaged. The percent volume fibrosis was determined using the method described 
previously (108). 
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3.4. Statistical analysis 
Data were first analyzed for normal distribution using a normality test (Kolmogorov-
Smirnov) provided by SigmaStat. If data were normally distributed, it was presented as 
mean ± SE (standard error). If the data were not normally distributed, it was presented 
as median (±SE). Two-way ANOVA was used to test for differences between gene-
deficient mice and wild-type mice under control conditions and after hypoxia+SU5416.  
Comparisons were made with the Tukey method under the interaction term. Statistical 
significance was defined as P<0.05. 
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4. Results 
 
4.1. Effect of global DDAH1 KO on hypoxia+SU5416-induced PAH and RV 
hypertrophy 
Effect of global DDAH1 KO on changes of body weight after hypoxia+SU5416 
The body weight was monitored weekly as presented in Figure 3. There was no 
significant difference between wild type and global DDAH1 KO mice body weight at 1 
week and 2 weeks after hypoxia+SU5416. After 3 weeks of hypoxia+SU5416 however, 
global DDAH1 KO mice exhibited a slightly higher loss of body weight as compared to 
WT mice (82.02 ± 0.86 % of starting weight in wild type hypoxia+SU5416 group versus 
78.99 ± 0.86 % in global DDAH1 KO hypoxia+SU5416 group; p<0.05). The results 
indicate that hypoxia+SU5416 caused a similar reduction of body weight in both wild 
type and Global DDAH1 KO mice, with DDAH1 KO being slightly more susceptible to 
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Weeks after Sugen injection (W)






















Figure 3.  Effect of hypoxia on body weight changes in wild type and global DDAH1 KO 
mice. Wild type and global DDAH1 KO mice were exposed to hypoxia+SU5416 
treatment for 3 weeks and the change (%) of body weight were determined. # indicates 
p<0.05 comparing WT to KO. 
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Global DDAH1 KO abolished lung DDAH1 expression and DDAH activity. 
We determined expression of lung DDAH1 and DDAH2 and total DDAH activity in wild 
type and global DDAH1 KO mice. DDAH1 expression was undetectable in lungs of 
global DDAH1 KO mice. DDAH2 expression was unchanged in lungs of global DDAH1 
KO mice (Figure 4A). As anticipated, total lung DDAH activity was abolished in global 
DDAH1 KO mice (Figure 4B).   
Figure 4.  Global DDAH1 KO abolished lung DDAH1 expression and DDAH activity. 
Representative picture of lung DDAH1 and DDAH2 expression by western blot is 
presented (A). Lung DDAH activity is presented (B). Data are presented as mean ± SEM. 
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Global DDAH1 KO impact on hypoxia+SU5416-induced increases of RV pressure 
RV pressure was assessed as a surrogate of the pulmonary arterial pressure in wild type 
and global DDAH1 KO mice under control and hypoxia+SU5416 conditions (Figure 5). 
RV systolic pressure, RV end-diastolic pressure, RV dp/dtmax, and RV dp/dtmin were 
not different between wild type and global DDAH1 KO mice under control conditions 
(Figure 6, Figure 7 and Table 2). However, global DDAH1 KO significantly exacerbated 
hypoxia+SU5416-induced increases of RV systolic pressure (42.84 ± 1.73 mmHg in wild 
type hypoxia+SU5416 group versus 48.28 ± 1.18 mmHg in global DDAH1 KO 
hypoxia+SU5416 group; p<0.05)  in  (Figure 6 and Table 2), RV dp/dtmax (3026.62 ± 
166.23 mmHg/s in wild type hypoxia+SU5416 group versus 3475.10 ± 152.54 mmHg/s 
in global DDAH1 KO hypoxia+SU5416 group; p<0.05) , and RV dp/dtmin (-2892.04 ± 
232.64 mmHg/s in wild type hypoxia+SU5416 group versus -3179.00 ± 209.62 mmHg/s 
in global DDAH1 KO hypoxia+SU5416 group; p<0.05)  (Figure 7 and Table 2). Global 
DDAH1 KO did not affect RV end diastolic pressure (RV EDP) in mice after 
hypoxia+SU5416 (Figure 6). 























Figure 5.  Representative RV pressure tracings from wild type and global DDAH1 KO 
mice exposed to sham and hypoxia+SU5416 conditions.  
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Table 2. Hemodynamic data for WT and global DDAH1 KO under sham and 
hypoxia+SU5416 conditions 
  
Data are presented as mean ± SEM when normally distributed. *p<0.05 as compared 
with corresponding control conditions; † p<0.05 as compared with WT mice under the 









Number of mice 6 6 9 8 
Heart rate (beat/min) 565.83±10.53 551.88±11.13 537.46±17.46 535.82±12.75 
RVSP (mmHg) 24.93±1.07 25.19±0.88 42.84±1.73* 48.28±1.18*† 
RVEDP(mmHg) 1.35±0.19 1.59±0.29 1.68±0.19 1.89±0.22 
RV dp/dt max (mmHg/s) 2508.56±308.79 2537.52±137.81 3026.62±166.23 3475.10±152.54*† 
RV dp/dt min (mmHg/s) -2095.01±334.60 -2351.91±132.89 -2892.04±232.64* -3179.00±209.62*† 







Figure 6. Global DDAH1 KO impact on hypoxia+SU5416 induced increase of RV 
pressure. RV pressure measurements were obtained by catheterization of right ventricle. 
RV systolic pressure and RV diastolic pressure were calculated from 7-9 mice in each 
group.  Data were presented as mean ± SEM. * indicates p<0.05 comparing 






































Hypoxia+SU5416               p<0.01 
KO                                       p=0.03 
Hypoxia+SU5416 × KO      p<0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416               p=0.20 
KO                                       p=0.27 
Hypoxia+SU5416 × KO      p=0.19 
 






Figure 7. Global DDAH1 KO impact on hypoxia+SU5416-induced increase of RV 
contractility. RV dp/dtmax and RV dp/dtmin were calculated from 7-9 mice in each group. 
Data were presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to 














































Hypoxia+SU5416               p<0.01 
KO                                       p=0.43 
 Hypoxia+SU5416 × KO      p<0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416               p<0.01 
KO                                       p=0.44 
Hypoxia+SU5416 × KO      p<0.05 
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Global DDAH1 KO exacerbated hypoxia+SU5416 induced increases of RV 
hypertrophy 
We measured the RV weight to body weight and ratio of the RV weight to LV (LV + 
septum) weight to determine RV hypertrophy under control and hypoxia+SU5416 
conditions. Global DDAH1 KO had no detectable effect of RV hypertrophy under control 
conditions as indicated by the similar ratios of RV weight to LV weight between global 
DDAH1 KO mice and wild type mice, as well as comparable RV weight and RV weight 
ratios to body weight. Consistent with the greater increase of RV systolic pressure in 
global DDAH1 KO mice after hypoxia+SU5416, global DDAH1 KO mice exhibited a 
significantly greater increase of RV to body weight ratio (1.42 ±  0.07 mg/g in wild type 
hypoxia+SU5416 group versus 1.62  ±  0.04 mg/g in KO hypoxia+SU5416 group; 
p<0.05) and RV to LV (LV + septum) ratio (0.38 ± 0.02 mg/g in wild type 
hypoxia+SU5416 versus 0.43 ± 0.01 mg/g in KO hypoxia+SU5416; p<0.05) compared to 
wild type mice after hypoxia+SU5416 (Figure 8 and Table 3), indicating that global 
DDAH1 KO exacerbated hypoxia-induced RV hypertrophy. In addition, Histological 
analysis indicated that hypoxia+SU5416 increased RV cell size to a greater degree in 
global DDAH1 KO mice as compared to wild type mice (362.47 ± 10.69 µm2 in wild type 
hypoxia+SU5416 group versus 410.81 ± 17.35 µm2 in KO hypoxia+SU5416 group)  
(Figure 9 and 10). 
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Table 3. Anatomic data for WT and DDAH1 KO mice under sham and hypoxia+SU5416 
conditions 
Data are presented as mean ± SEM when normally distributed. *p<0.05 as compared 
with corresponding sham conditions; † p<0.05 as compared with WT mice under the 








Number of mice 10 14 22 22 
Bodyweight (BW) (g) 33.16 ± 2.56 30.32 ± 0.85 29.11 ± 0.55 29.37 ± 0.49 
Tibia length (TL) (mm) 17.56 ± 0.23 17.53 ± 0.09 18.03 ± 0.05 18.33 ± 0.06* 
RV weight (mg) 29.07 ±  1.96 27.51 ± 0.57 41.34 ± 2.30* 47.57 ± 1.33*† 
LV + septum (mg) 101.75 ± 6.88 95.41 ± 1.78 110.66 ± 3.36 110.96 ± 3.38* 
Ratio of RV to LV + septum 0.29± 0.01 0.29 ± 0.01 0.38 ± 0.02* 0.43± 0.01*† 
Lung mass (mg) 158.64 ± 7.55 147.27 ± 2.61 213.34 ± 3.36* 222.00 ± 3.63*† 
Right atria weight (mg) 3.53 ± 0.17 3.48 ± 0.10 6.39 ± 0.52* 6.48 ± 0.62* 
Left atria weight (mg) 4.00 ± 0.20 3.76 ± 0.14 5.34 ± 0.25* 5.36 ± 0.35* 
Kidney weight (mg) 378.92 ± 21.38 357.79 ± 16.99 338.48 ± 5.91 356.20 ± 8.61 
Ratio of RV to BW (mg/g) 0.89 ± 0.03 0.91 ± 0.03 1.42± 0.07* 1.62 ± 0.04*† 
Ratio of LV to BW (mg/g) 3.12 ± 0.15 3.17 ± 0.09 3.80 ± 0.09* 3.78± 0.10* 
Ratio of lung to BW (mg/g) 4.93 ± 0.25 4.90 ± 0.15 7.37 ± 0.15* 7.57 ± 0.11* 
Ratio of RA to BW (mg/g) 0.11 ± 0.01 0.12 ± 0.01 0.25 ± 0.03* 0.23 ± 0.02* 
Ratio of LA to BW (mg/g) 0.13 ± 0.01 0.14 ± 0.01 0.22± 0.02* 0.22 ± 0.02* 
Ratio of kidney to BW (mg/g) 11.68 ± 0.52 11.85 ± 0.57 11.67 ± 0.23 12.16 ± 0.28 
Ratio of RV to TL (mg/mm) 1.65 ± 0.09 1.57 ± 0.04 2.29 ± 0.13* 2.60 ± 0.07*† 
Ratio of LV to TL (mg/mm) 5.77 ± 0.32 5.36 ± 0.09 6.13 ± 0.18 6.06 ± 0.18* 
Ratio of lung to TL (mg/mm) 9.01 ± 0.36 8.27 ± 0.14 11.83 ± 0.19* 12.11 ± 0.37* 
Ratio of RA to TL (mg/mm) 0.20 ± 0.01 0.20 ± 0.01 0.41 ± 0.04* 0.41 ± 0.29* 
Ratio of LA to TL (mg/mm) 0.23 ± 0.01 0.21 ± 0.01 0.30 ± 0.01* 0.29 ± 0.02* 
Ratio of kidney to TL (mg/mm) 21.49 ± 0.98 20.03 ± 1.08 18.77 ± 0.32* 19.47 ± 0.47 





Figure 8. Global DDAH1 KO exacerbated hypoxia+SU5416-induced increase of RV 
hypertrophy. Hearts were collected. Right ventricle weight to body weight ratio and right 
ventricle weight to left ventricle + septum weight ratios were calculated from 10 to 22 
samples in each group. Data were presented as mean ± SEM. * indicates p<0.05 





























Hypoxia+SU5416               p<0.01 
KO                                       p=0.01 
Hypoxia+SU5416 × KO      p<0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416               p<0.01 
KO                                       p=0.01 
Hypoxia+SU5416 × KO      p=0.03 
 




























Figure 9. Representative images of RV cell size with WGA staining from wild type and 
global DDAH1 KO mice exposed to sham and hypoxia+SU5416 conditions.   














Figure 10. Global DDAH1 KO impact on hypoxia+SU5416 induced increases of RV cell 
size. Right ventricular tissue was fixed and stained with WGA for cardiomyocyte cell size 
from wild type and global DDAH1 KO mice. Cardiomyocyte cell size was calculated from 
5 samples in each group. Data were presented as mean ± SEM. * indicates p<0.05 
comparing hypoxia+SU5416 to sham. # indicates P<0.05 comparing WT to KO. 























Hypoxia+SU5416               p<0.01 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p<0.05 
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Global DDAH1 KO exacerbated hypoxia+SU5416-induced increases of RV fibrosis 
To determined right ventricular fibrosis in global DDAH1 KO and wild type mice under 
control and hypoxia+SU5416 conditions, Sirius red staining was performed on 5 samples 
in each group. Representative pictures of RV staining were illustrated in Figure 11. 
There was no significant difference between global DDAH1 KO mice and wild type mice 
under control conditions. Hypoxia+SU5416 increased RV fibrosis to a greater degree in 
global DDAH1 KO mice as compared to wild type mice (6.17 ± 0.34 % in wild type 
hypoxia+SU5416 group versus 7.27 ± 0.20 % in global DDAH1 KO hypoxia+SU5416 
group; p<0.05) (Figure12). 
 


























Figure 11. Sirius red stained cross-sections of right ventricles from wild type and global 
DDAH1 KO mice. The right ventricle cross-sections (20X) were stained with Sirius red 
from wild type and global DDAH1 KO mice under sham and hypoxia+SU5416 conditions.   













Figure 12. Global DDAH1 KO exacerbated hypoxia+SU5416-induced increase of RV 
fibrosis. Right ventricular sections were stained with Sirius red in wild type and global 
DDAH1 KO mice under sham and hypoxia+SU5416 conditions. The average percent of 
right ventricular fibrosis was calculated from 5 samples in each group. Data were 
presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to sham. # 





















Hypoxia+SU5416               p<0.01 
KO                                       p=0.01 
Hypoxia+SU5416 × KO      p=0.04 
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Global DDAH1 KO aggravated hypoxia+SU5416-induced pulmonary vascular 
remodeling and pulmonary fibrosis 
To determine the effect of global DDAH1 KO on pulmonary vascular remodeling, we 
determined the percentage of non-muscularized (NM), partially muscularized (PM), and 
fully muscularized small arteries (FM) in wild type and global DDAH1 KO mice under 
sham conditions and 3 weeks after hypoxia+SU5416 (Figure 13 and 14). Hematoxylin 
stained histological characteristics of lung tissue with global DDAH1 KO and wild type 
mice were illustrated in Figure 13. The percentage of non-muscularized, partially 
muscularized and fully muscularized small arteries in lung tissues was not different 
between wild type mice and global DDAH1 KO mice under sham conditions (Figure 13 
and 14). Exposure to hypoxia caused increases in fully muscularized small arteries in 
wild type and global DDAH1 KO mice (Figure 14). The increases were greater in the 
global DDAH1 KO mice (p<0.05). As expected, hypoxia also resulted in a decreased 
number of non-muscularized small arteries in both wild type and global DDAH1 KO mice 
(Figure 14).  
In addition, pulmonary fibrosis was detected using Masson trichrome staining under 
sham conditions and 3 weeks post hypoxia+SU5416 (Figure 15). Pulmonary fibrosis was 
comparable between global DDAH1 KO mice and wild type mice under sham conditions 
(Figure 16). Hypoxia+SU5416 caused pulmonary fibrosis in both wild type mice and 
global DDAH1 KO mice, but increases were significantly greater in the global DDAH1 
KO mice than in the wild type mice (5.35 ± 0.63 % in wild type hypoxia+SU5416 group 
versus 8.40 ± 1.0. % in global DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 15 
and 16). 
 

























Figure 13.  Representative images of pulmonary vascular remodeling. Lungs from wild 
type and global DDAH1 KO mice exposed to sham and hypoxia+SU5416 conditions 
were flushed, fixed in formalin, and stained using eosin-hemotoxylin for pulmonary 
vessel muscularization. 
 













Figure 14. Global DDAH1 KO aggravated hypoxia+SU5416-induced pulmonary vascular 
remodeling. The average percent of non-muscularized, partially muscularized, and fully 
muscularized pulmonary arterioles were calculated from 5 samples in each group. Data 
were presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to 































































Figure 15.  Representative images of lung fibrosis from wild type and global DDAH1 KO 
mice. Lungs from wild type and global DDAH1 KO mice exposed to sham or 
hypoxia+SU5416 conditions were flushed, fixed in formalin, and stained using trichrome 
stain for pulmonary fibrosis.   











Figure 16. Global DDAH1 KO aggravated hypoxia+SU5416-induced pulmonary fibrosis. 
Lung sections were stained with trichrome in wild type and global DDAH1 KO mice 
under sham and hypoxia+SU5416 conditions. The average percent of lung fibrosis was 
calculated from 5 samples in each group. Data were presented as mean ± SEM. * 
indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates P<0.05 comparing 

























Hypoxia+SU5416               p<0.01 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p=0.02 
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Hypoxia+SU5416 increased eNOS expression in wild type and global DDAH1 KO 
mice 
Expression of DDAH1 and eNOS proteins were determined by Western blotting (Figure 
17). Western blot demonstrated that lung DDAH1 expression was not detectable in 
global DDAH1 KO mice under sham conditions and after hypoxia+SU5416 as expected 
(Figure 17 ). Hypoxia+SU5416 caused no change in lung DDAH1 expression in wild type 
mice (Figure 17). Lung eNOS expression was not significantly different between wild 
type and global DDAH1 KO mice under sham conditions (Figure 17), while 
hypoxia+SU5416 increased lung eNOS expression in both wild type and global DDAH1 
KO mice (0.47 ± 0.07 in wild type sham group versus 1.76 ± 0.33 in wild type 
hypoxia+SU5416 group; p<0.05) (0.51 ± 0.06 in global DDAH1 KO sham group versus 
1.51 ± 0.13 in global DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 17).  














Figure 17. Hypoxia+SU5416 increased eNOS expression in wild type and global DDAH1 
KO mice. Data were presented as mean ± SEM. * indicates p<0.05 comparing 
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Hypoxia+SU5416               p<0.01 
KO                                       p=0.29 
Hypoxia+SU5416 × KO      p=0.19 
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Effects of hypoxia+SU5416 and global DDAH1 KO on DDAH activity  
To determine global DDAH1 KO affect on DDAH activity under control and 
hypoxia+SU5416 conditions, lung DDAH activity was determined. Global DDAH1 KO 
almost abolished lung DDAH activity under control conditions and after hypoxia+SU5416 
(Figure 18). Hypoxia+SU5416 caused decreased lung DDAH activity in wild type (27.65 
± 1.88 nmol/g/min in wild type sham group versus 16.64 ± 2.11 nmol/g/min in wild type 
hypoxia+SU5416 group; p<0.05), while slightly increasing DDAH activity in global 
DDAH1 KO mice (1.04 ± 0.69 nmol/g/min in global DDAH1 KO sham group versus 3.01 
± 0.83 nmol/g/min in global DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 18). 
The lung DDAH activity was significantly different between wild type and global DDAH1 
KO mice under both sham and hypoxia+SU5416 conditions (27.65 ± 1.88 nmol/g/min in 
wild type sham group versus 1.04 ± 0.69 nmol/g/min in global DDAH1 KO sham group; 
p<0.05) 16.64 ± 2.11 nmol/g/min in wild type hypoxia+SU5416 group versus 3.01 ± 0.83 
nmol/g/min in global DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 18).    












Figure 18. Effects of hypoxia+SU5416 and global DDAH1 KO on DDAH activity. Data 
were presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to 





























Hypoxia+SU5416               p<0.05 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p<0.01 
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Global DDAH1 KO increased lung ADMA without affecting lung SDMA content 
under control and hypoxia+SU5416 conditions 
To determine the effect of global DDAH1 KO on lung ADMA and SDMA content under 
control and hypoxia conditions, we determined the ADMA and SDMA content from the 
lung. Lung ADMA content was significantly increased in global DDAH1 KO mice under 
sham conditions and after hypoxia+SU5416 (55.01 ± 9.70 nmol/g in wild type sham 
group versus 92.05 ± 10.17 nmol/g in global DDAH1 KO sham group; p<0.05) (67.60 ± 
9.27 nmol/g in wild type hypoxia+SU5416 group versus 92.83 ± 8.97 nmol/g in global 
DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 19). Lung SDMA was not different 
in wild type mice or global DDAH1 KO mice under sham conditions and after 
hypoxia+SU5416 (Figure 19). 
 













Figure 19. Global DDAH1 KO increased lung ADMA without affecting lung SDMA 
content under sham and hypoxia+SU5416 conditions. Lung ADMA and SDMA were 
determined using a high-through put liquid chromatographic-tandem mass spectrometric 
method. Data were presented as mean ± SEM. * indicates p<0.05 comparing 



















































Hypoxia+SU5416               p=0.34 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p=0.28 
 
2-WAY ANOVA 
Hypoxia+SU5416               p=0.29 
KO                                       p=0.27 
Hypoxia+SU5416 × KO      p=0.21 
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Global DDAH1 KO did not affect the expression of lung PRMT1, PRMT3, and CAT1  
Western blot showed that lung PRMT1 and CAT1 expression were not altered by 
hypoxia+SU5416 or by global DDAH1 KO (Figure 20). Lung PRMT3 expression was 
significantly increased in response to hypoxia+SU5416 in both wild type (1.00 ± 0.06 in 
wild type sham group versus 1.34 ± 0.11 in wild type hypoxia+SU5416 group; p<0.05) 
and global DDAH1 KO mice (0.90 ± 0.06 in global DDAH1 KO sham group versus 1.21 ± 
0.08 in global DDAH1 KO hypoxia+SU5416 group; p<0.05), but no difference was 
observed between WT and global DDAH1 KO mice (Figure 20). 












Figure 20. Global DDAH1 KO did not affect the protein expression of lung PRMT1, 
PRMT3, and CAT1. Data were presented as mean ± SEM. * indicates p<0.05 comparing 















































































Hypoxia+SU5416              p=0.27 
KO                                      p=0.13 
Hypoxia+SU5416 × KO     p=0.23 
2-WAY ANOVA 
Hypoxia+SU5416              p<0.01 
KO                                      p=0.08 
Hypoxia+SU5416 × KO     p=0.48 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.44 
KO                                      p=0.23 
Hypoxia+SU5416 × KO     p=0.45 
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Global DDAH1 KO cause accumulation of plasma ADMA under control and 
hypoxia+SU5416 conditions 
Plasma ADMA content was significantly increased in global DDAH1 KO mice as 
compared with wild type mice under control conditions (0.62 ± 0.05 µmol in wild type 
sham group versus 1.25 ± 0.11 µmol in global DDAH1 KO sham group; p<0.05) and 
further elevated in response to hypoxia+SU5416 (0.86 ± 0.10 µmol in wild type 
hypoxia+SU5416 group versus 1.91 ± 0.20 µmol in global DDAH1 KO hypoxia+SU5416 
group; p<0.05) (Figure 21). While hypoxia+SU5416 increased plasma ADMA content in 
wild type (0.62 ± 0.05 µmol in wild type sham group versus 0.86 ± 0.10 µmol in wild type 
hypoxia+SU5416 group; p<0.05), this increase was significantly greater in global DDAH1 
KO mice (1.25 ± 0.11 µmol in global DDAH1 KO sham group versus 1.91 ± 0.20 µmol in 
global DDAH1 KO hypoxia+SU5416 group; p<0.05) (Figure 21). Plasma L-Arginine 
content was not significantly different between wild type and global DDAH1 KO mice 
under sham and hypoxia+SU5416 conditions (Figure 21). Hypoxia+SU5416 also 
induced no significant changes in L-Arginine content in wild type and global DDAH1 KO 
mice (Figure 21). The ratio of plasma ADMA to L-Arginine, a common indicator of 
systemic nitric oxide bio availability, was significantly increased in global DDAH1 KO 
mice under sham and after hypoxia+SU5416 in comparison to WT mice (Figure 21). 












Figure 21. Global DDAH1 KO caused accumulation of plasma ADMA under sham and 
hypoxia+SU5416 conditions. Plasma ADMA and L-Arginine were determined by a high 
through put chromatographic-tandem mass spectrometric method. Data were presented 
as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates 



















































































Hypoxia+SU5416              p<0.01 
KO                                      p<0.01 
Hypoxia+SU5416 × KO     p<0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.06 
KO                                      p=0.12 
Hypoxia+SU5416 × KO     p=0.42 
 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.09 
KO                                      p=0.03 
Hypoxia+SU5416 × KO     p=0.48 
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Global DDAH1 KO increased plasma L-NMMA accumulation under control 
conditions and in response to hypoxia+SU5416 
Plasma L-NMMA content was significantly higher in global DDAH1 KO mice than WT 
mice under sham conditions (0.18 ± 0.02 µmol in wild type sham group versus 0.69 ± 
0.14 µmol in global DDAH1 KO sham group; p<0.05) and further increased in response 
to hypoxia+SU5416 (0.22 ± 0.05 µmol in wild type hypoxia+SU5416 group versus 0.97 ± 
0.06 µmol in global DDAH1 KO hypoxia+SU5416 group; p<0.05). Hypoxia+SU5416 
increased plasma L-NMMA content in global DDAH1 KO mice (from 0.69 ± 0.14 µmol in 
global DDAH1 KO sham group to 0.97 ± 0.06 µmol in global DDAH1 KO 
hypoxia+SU5416 group; p<0.05) (Figure 22). Plasma L-Arginine content was not 
significantly different between wild type and global DDAH1 KO mice under sham or 
hypoxia+SU5416 conditions (Figure 22). Hypoxia+SU5416 also caused no changes in L-
Arginine content wild type or global DDAH1 KO mice (Figure 22). The ratio of plasma 
ADMA to L-arginine was significantly increased in global DDAH1 KO mice under sham 
and after hypoxia+SU5416 (Figure 22).  














Figure 22. Global DDAH1 KO increased plasma L-NMMA accumulation under sham 
conditions and in response to hypoxia+SU5416. Plasma L-NMMA and L-Arginine were 
determined by a high through put chromatographic-tandem mass spectrometric method. 
Data were presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to 

















































































Hypoxia+SU5416              p<0.05 
KO                                      p<0.01 
Hypoxia+SU5416 × KO     p=0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.06 
KO                                      p=0.12 
Hypoxia+SU5416 × KO     p=0.41 
 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.22 
KO                                      p<0.01 
Hypoxia+SU5416 × KO     p=0.32 
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Global DDAH1 KO had no effect on hypoxia+SU5416 induced plasma SDMA 
contents  
Plasma SDMA content was determined by high through put chromatographic-tandem 
mass spectrometric method. Plasma SDMA content was not significantly different 
between wild type mice and global DDAH1 KO mice under sham and hypoxia+SU5416 
conditions but significantly increased in both wild type (0.17 ± 0.01 µmol in wild type 
sham group versus 0.28 ± 0.04 µmol in wild type hypoxia+SU5416 group; p<0.05) and 
global DDAH1 KO mice after hypoxia+SU5416 (0.19 ± 0.02 µmol in global DDAH1 KO 
sham group versus 0.38 ± 0.05 µmol in global DDAH1 KO hypoxia+SU5416 group; 
p<0.05) (Figure 23). This indicates that DDAH1 does not regulate plasma SDMA levels. 
 














Figure 23. Global DDAH1 KO had no effect on hypoxia+SU5416-induced plasma SDMA 
contents. Plasma SDMA content was determined by a high through put 
chromatographic-tandem mass spectrometric method. Data were presented as mean ± 
SEM. * indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates P<0.05 



























Hypoxia+SU5416               p<0.01 
KO                                       p=0.06 
Hypoxia+SU5416 × KO      p=0.12 
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4.2. Effect of cardio DDAH1 KO on hypoxia+SU5416-induced PAH and RV 
hypertrophy 
 
Cardio-DDAH1 KO has no effect of RV hypertrophy under sham conditions but 
exacerbates hypoxia+SU5416-induced RV hypertrophy 
Body weight, RV weight, and LV weight (LV + Septum) were measured to examine RV 
hypertrophy in wild type and cardio-DDAH1 KO mice under sham and hypoxia+SU5416 
conditions.  RV to body weight and ratio of RV to LV (LV + Septum) weight were not 
significantly different between wild type and cardio-DDAH1 KO mice under sham 
conditions (Table 4 and Figure 24).  However, cardio-DDAH1 KO significantly 
exacerbated hypoxia+SU5416-induced increases of RV hypertrophy as indicated by the 
ratio of RV to body weight (1.82 ± 0.08 mg/g in wild type hypoxia+SU5416 group versus 
2.26 ± 0.12 mg/g in KO hypoxia+SU5416 group; p<0.05) and RV to LV (LV + Septum) 
weight (0.33 ± 0.01 mg/g in wild type hypoxia+SU5416 group versus 0.37 ± 0.02 mg/g in 
KO hypoxia+SU5416 group; p<0.05). Interestingly, the RV systolic pressure and RV 
dp/dtmax were not significantly different between wild type and cardio-DDAH1 KO mice 
after hypoxia+SU5416 (Figure 27 and 28). RV cell size, another indicator of hypertrophy, 
was determined by WGA staining. Histological analysis indicated that hypoxia+SU5416 
caused a significant increase of RV cell size in both wild type and cardio-DDAH1 KO 
mice but the increase of RV cell size was significantly greater in cardio-DDAH1 KO mice 
(343.79 ± 9.76 µm2 in wild type hypoxia+SU5416 group versus 409.69 ± 21.70 µm2 in 
KO hypoxia+SU5416 group) (Figure 25 and 26). 
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Table 4. Anatomic data for WT and cardio-DDAH1 KO mice under sham and 
hypoxia+SU5416 conditions 
Data are presented as mean ± SEM when normally distributed. *p<0.05 as compared 
with corresponding sham conditions; † p<0.05 as compared with WT mice under the 
hypoxia+SU5416 condition 







Number of mice 8 8 11 9 
Bodyweight (g) 27.78 ± 1.64 28.80 ± 2.67 27.24 ± 0.72 25.10 ± 1.00† 
Tibia length (mm) 17.46 ± 0.12 17.57 ± 0.24 17.83 ± 0.05 17.73 ± 0.11* 
RV weight (mg) 26.95 ± 2.03 30.19 ± 2.52 49.12 ± 1.66* 56.89 ± 3.63*† 
LV + septum (mg) 133.24 ± 11.60 131.93 ± 14.22 148.72 ± 4.99 153.61 ± 7.29 
Ratio of RV to LV + septum 0.20 ± 0.08 0.24 ± 0.01 0.33 ± 0.01* 0.37 ± 0.02*† 
Lung mass (mg) 140.36 ± 7.81 138.23 ± 10.98 191.23 ± 4.18* 190.27 ± 13.48* 
Right atria (mg) 3.00 ± 0.25 3.21 ± 0.36 4.44 ± 0.27* 9.10 ± 3.39* 
Left atria weight (mg) 5.35 ± 0.67 5.23 ± 0.74 6.24 ± 0.43 6.83 ± 0.59 
Kidney weight (mg) 368.76 ± 29.59 435.41 ± 53.69 320.46 ± 10.29* 326.24 ± 24.43* 
Ratio of RV to BW (mg/g) 0.97 ± 0.05 1.06 ± 0.05 1.82± 0.08* 2.26 ± 0.12*† 
Ratio of LV to BW (mg/g) 4.75 ± 0.18 4.54 ± 0.16 5.49 ± 0.22* 6.12 ± 0.21*† 
Ratio of lung to BW (mg/g) 5.14 ± 0.34 4.88 ± 0.20 7.07 ± 0.22* 7.52 ± 0.32* 
Ratio of RA to BW (mg/g) 0.11 ± 0.01 0.11 ± 0.01 0.17 ± 0.01* 0.37 ± 0.14* 
Ratio of LA  to BW (mg/g) 0.19 ± 0.02 0.18 ± 0.02 0.23 ± 0.02* 0.27 ± 0.02* 
Ratio of kidney to BW (mg/g) 13.19 ± 0.43 14.82 ± 0.62 11.85 ± 0.45* 12.92 ± 0.78* 
Ratio of RV to TL (mg/mm) 1.55 ± 0.12 1.71 ± 0.13 2.76 ± 0.09* 3.20 ± 0.20*† 
Ratio of LV to TL (mg/mm) 7.66 ± 0.70 7.45 ± 0.74 8.35 ± 0.29 8.67 ± 0.42 
Ratio of lung  to TL (mg/mm) 8.04 ± 0.44 7.83 ± 0.54 10.73 ± 0.25* 10.74 ± 0.79* 
Ratio of RA  to TL (mg/mm) 0.17 ± 0.01 0.18 ± 0.02 0.25 ± 0.01* 0.51 ± 0.19*† 
Ratio of LA to TL (mg/mm) 0.31 ± 0.04 0.30 ± 0.04 0.35 ± 0.02 0.39 ± 0.03 
Ratio of kidney to TL (mg/mm) 21.18 ± 1.78 24.56 ± 2.80 17.97 ± 0.57* 18.39 ± 1.37* 














Figure 24. Cardio-DDAH1 KO exacerbated hypoxia+SU5416-induced increase of RV 
hypertrophy. After 3 weeks exposure to hypoxia+SU5416 or sham conditions, hearts 
were collected. Right ventricle weight to body weight ratio, right ventricle weight to left 
ventricle + septum weight were calculated from 8 to 11 samples in each group. Data 
were presented as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to 

































Hypoxia+SU5416               p<0.01 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p<0.05 
 
2-WAY ANOVA 
Hypoxia+SU5416               p<0.01 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p<0.05 
 


























Figure 25. Representative images of RV cell size with WGA staining from wild type and 
cardio-DDAH1 KO mice exposed to sham and hypoxia+SU5416 conditions.   














Figure 26. Cardio-DDAH1 KO exacerbated hypoxia+SU5416-induced increase of RV 
cell size. Right ventricular tissue from wild type and cardio-DDAH1 KO mice was fixed 
and stained with WGA for cardiomycyte cell size. Cardiomycyte cell size was calculated 
from 5 samples in each group. Data were presented as mean ± SEM. * indicates p<0.05 

























Hypoxia+SU5416               p<0.01 
KO                                       p<0.01 
Hypoxia+SU5416 × KO      p<0.01 
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Cardio-DDAH1 KO exacerbated hypoxia+SU5416-induced increase of RV 
hypertrophy but had no significant effect on RV pressure 
To determine whether cardio specific DDAH1 influences PAH development, we 
examined the effect of cardio-DDAH1 KO on hypoxia+SU5416-induced PAH in mice. RV 
systolic pressure, RV end diastolic pressure, RV dp/dtmax, and RV dp/dtmin were not 
different between wild type and Cardio-specific DDAH1 KO mice under sham condition 
(Table 5 and Figure 27 and 28). The RV systolic pressure and RV dp/dtmax were also 
not significantly different between wild type and cardio-DDAH1 KO mice after 
hypoxia+SU5416 (Table 4, Figure 27, and 28). Hypoxia+SU5416 increased RV systolic 
pressure and RV dp/dtmax in both wild type (20.89 ± 0.84 mmHg in wild type sham 
group versus 38.53 ± 1.45 mmHg in wild type hypoxia+SU5416 group; p<0.05) and 
cardio-DDAH1 KO mice (20.65 ± 0.70 mmHg in cardio-DDAH1 KO sham group versus 
40.34 ± 5.06 mmHg in cardio-DDAH1 KO hypoxia+SU5416 group; p<0.05). Cardio-
DDAH1 KO mice exhibited no significant difference in RV diastolic pressure as 
compared with wild type mice under both sham and hypoxia+SU5416 conditions (Figure 
27).  
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Table 5. Hemodynamic data for WT and cardio-DDAH1 KO mice under sham and 
hypoxia+SU5416 conditions 
 
Data are presented as mean ± SEM when normally distributed. *p<0.05 as compared 
with corresponding sham conditions; † p<0.05 as compared with WT mice under the 











Number of mice 6 7 8 5 
Heart rate (beat/min) 541.45±13.55 548.65±9.86 491.39±7.04* 477.20±9.83* 
RV systolic pressure (mmHg) 20.46±0.85 20.65±0.70 37.81±1.43* 39.94±3.94* 
RV end diastolic pressure 
(mmHg) 
1.02±0.21 1.34±0.27 1.80±0.39 2.20±1.00 
RV dp/dt max (mmHg/s) 1838.04±140.56 1940.92±145.08 2437.52±114.21* 2488.26±95.38* 
RV dp/dt min (mmHg/s) -1645.03±121.39 -1811.87±153.07 -2303.46±86.61* -2327.43±123.31* 














Figure 27. Cardio-DDAH1 KO had no significant effect on hypoxia+SU5416-induced RV 
pressure.  To measure RV systolic pressure and RV diastolic pressure, RV 
catheterization was performed. Data were presented as mean ± SEM. * indicates p<0.05 







































Hypoxia+SU5416               p<0.01 
KO                                       p=0.27 
Hypoxia+SU5416 × KO      p=0.30 
 
2-WAY ANOVA 
Hypoxia+SU5416               p=0.06 
KO                                       p=0.23 
Hypoxia+SU5416 × KO      p=0.46 
 













Figure 28. Cardio-DDAH1 KO had no significant effect on hypoxia+SU5416-induced RV 
contractility. Data were presented as mean ± SEM. * indicates p<0.05 comparing 












































Hypoxia+SU5416               p<0.01 
KO                                       p=0.28 
Hypoxia+SU5416 × KO      p=0.42 
 
2-WAY ANOVA 
Hypoxia+SU5416               p<0.01 
KO                                       p=0.22 
Hypoxia+SU5416 × KO      p=0.28 
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Cardio-DDAH1 KO did not affect hypoxia+SU5416-induced RV fibrosis 
Sirius red staining was used to determine right ventricular fibrosis in wild type and under 
sham and hypoxia+SU5416 conditions (n=5 samples each group. Representative 
pictures of RV staining are shown in Figure 29. While hypoxia+SU5416 increased RV 
fibrosis in wild type and cardio-DDAH1 KO mice (2.89 ± 0.34 % in wild type sham group 
versus 5.97 ±  0.34 % in wild type hypoxia+SU5416 group and 2.98 ± 0.25 % in KO 
sham group versus 6.98 ± 0.88 % in KO hypoxia+SU5416 group; p<0.05). No significant 
difference in fibrosis was observed between cardio-DDAH1 KO mice and wild type mice 
under sham or hypoxia+SU5416 conditions. 
 


























Figure 29. Representative images of RV fibrosis. Right ventricle cross-sections (20X) 
were stained with Sirius red from wild type and cardio-DDAH1 KO mice under sham and 
hypoxia+SU5416 conditions.   
 














Figure 30. Cardio-DDAH1 KO did not affect hypoxia+SU5416-induced RV fibrosis. RV 
sections from wild type and cardio-DDAH1 KO mice under sham and hypoxia+SU5416 
conditions were stained with Sirius red. The average percent of right ventricular fibrosis 
was calculated from 5 samples in each group. Data were presented as mean ± SEM. * 
indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates P<0.05 comparing 























Hypoxia+SU5416               p<0.01 
KO                                       p=0.07 
Hypoxia+SU5416 × KO      p=0.12 
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Cardio-DDAH1 KO did not affect hypoxia+SU5416-induced pulmonary vascular 
remodeling 
To determine the effect of cardio-DDAH1 KO on pulmonary vascular remodeling, the 
percentages of non-muscularized (NM), partially muscularized (PM), and fully 
muscularized small arteries (FM) were determined in wild type and cardio-DDAH1 KO 
mice under control and  hypoxia+SU5416 conditions. The lung sections were stained 
with hematoxylin (n=5 samples from each group (Figure 31). The percentage of non-
muscularized, partially muscularized and fully muscularized small arteries in lung tissue 
was not different between wild type and cardio-DDAH1 KO mice under sham conditions 
(Figure 31 and 32). Hypoxia+SU5416 decreased the number of non muscularized small 
arteries and increased the number of partially muscularized and fully muscularized small 
arteries in both wild type and cardio-DDAH1 KO mice (Figure 32). There was no 
significant difference between wild type and cardio-DDAH1 KO mice under 
hypoxia+SU5416 conditions (Figure 32). 


























Figure 31. Representative images of pulmonary vascular remodeling. Lungs from wild 
type and cardio-DDAH1 KO mice exposed to sham and hypoxia+SU5416 conditions 
were flushed, fixed in formalin, and stained using eosin-hemotoxylin for pulmonary 
vessel muscularization 














Figure 32. Cardio-DDAH1 KO did not affect hypoxia+SU5416-induced pulmonary 
vascular remodeling. The average percent of non-muscularized, partially muscularized, 
and fully muscularized pulmonary arterioles were calculated from 5 samples in each 
group. Data were presented as mean ± SEM. * indicates p<0.05 comparing 
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Cardio-DDAH1 KO did not affect plasma ADMA, L-NMMA, and SDMA  
Plasma ADMA, L-NMMA and SDMA content were determined by high through put 
chromatographic-tandem mass spectrometric method in wild type and cardio-DDAH1 
KO mice under control and hypoxia+SU5416 conditions. Cardio-DDAH1 KO did not 
significantly alter plasma ADMA, L-NMMA, and SDMA content under sham or 
hypoxia+SU5416 conditions in compared to WT mice (Figure 33). 














Figure 33. Cardio-DDAH1 KO did not significantly increase plasma ADMA, L-NMMA, 
and SDMA. Plasma ADMA, L-NMMA, and SDMA contents were determined by a high 
through put chromatographic-tandem mass spectrometric method. Data were presented 
as mean ± SEM. * indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates 































































Hypoxia+SU5416              p=0.06 
KO                                      p=0.06 
Hypoxia+SU5416 × KO     p=0.42 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.10 
KO                                      p=0.32 
Hypoxia+SU5416 × KO     p=0.40 
2-WAY ANOVA 
Hypoxia+SU5416              p=0.06 
KO                                      p=0.06 
Hypoxia+SU5416 × KO     p=0.44 
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5. Discussion 
PAH increases the workload in the right ventricle, causing RV hypertrophy that 
eventually develops into right heart failure. DDAH1 regulates NO-cGMP signaling in part 
by degrading the NOS inhibitor ADMA. Because NO-cGMP signaling is important in both 
pulmonary vessels and in cardiomyocyte physiology, and DDAH1 is expressed in both of 
these tissues, it is difficult to distinguish whether DDAH1 regulation of PAH and 
subsequent RV hypertrophy is due to lung specific DDAH1 effects or through 
cardiomyocyte DDAH1 influence on the heart. Therefore, cardiomyocyte specific 
disruption of DDAH1 was used to determine cardiomyocyte DDAH1 impact on RV 
hypertrophy that occurs in response to PAH. Because DDAH1 KO in cardiomyocytes did 
not increase systemic ADMA levels, it   determines the specific impact of cardiac DDAH1 
on RV hypertrophy by comparing the response of wild type and cardio-DDAH1 KO 
hearts to similar degrees of PAH. Together, using of global and cardio-specific DDAH1 
KO provides new insight into the specific pulmonary and cardiac roles of DDAH1 in 
cardiovascular response to the stress imposed by PAH. 
 
Our data indicate that genetic disruption of global DDAH1 has no observable influence 
on pulmonary structure or right ventricular hemodynamics under basal conditions, but 
significantly exacerbates muscularization of pulmonary arteries, RV hypertrophy, lung 
fibrosis, and pulmonary vascular resistance (as indicated by increase right ventricular 
pressure) in response to hypoxia+SU5416. Global DDAH1 KO caused significant 
increases of NOS inhibitors ADMA and L-NMMA in the plasma under sham conditions. 
hypoxia+SU5416 further elevates the levels of these NOS inhibitors in global DDAH1 KO 
mice as compared to WT mice. Chronic hypoxia+SU5416 resulted in decreased DDAH1 
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activity and increased ADMA content in wild type mice, in agreement with the proposal 
that diminished DDAH1 activity in PAH promotes ADMA accumulation. However, cardio-
DDAH1 KO aggravated hypoxia+SU5416-induced increase of RV hypertrophy under 
apparently similar levels of PAH, indicated by ratios of RV to BW and RV to LV + S and 
without significantly higher levels of plasma. This suggests that distribution of DDAH1 in 
cardiomyocytes protects the heart against RV hypertrophy. Collectively, these findings 
indicate that DDAH1 plays an important role in protecting both the lung and heart from 
the development of PAH under hypoxia+SU5416 conditions. 
 
Impaired NO signaling is believed to play a role in development of PAH (109, 111). NO 
plays a vital role in endothelial smooth muscle cell coupling (26, 27) and pulmonary 
vascular tone (111, 112), inhibits platelet aggregation (113) and reduces leukocyte 
adhesion to vascular endothelium (114, 115). These events may be important early in 
PAH pathogenesis, which is believed to involve vasoconstriction (116, 117) and vascular 
inflammation (118, 119). NO also can reduce vascular smooth muscle cell proliferation 
(120), migration (121), and collagen synthesis (122). Conversely, endogenous NOS 
inhibitors ADMA and L-NMMA (17, 45) promote oxidative stress (123, 124), smooth 
muscle cell proliferation (125), and fibrosis (126), suggesting maintaining NO signaling is 
important for attenuating the vascular remodeling that is a hallmark of established PAH. 
Importantly plasma ADMA is commonly elevated in animal PAH models (7) and human 
PAH of various etiologies (127-130), while expression or activity of DDAH1 is reduced 
(7). Consistent with DDAH1 playing the major role in ADMA removal (6), ADMA levels 
were nearly doubled in the lungs and plasma of DDAH1 KO mice as compared to WT 
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mice. However, this did not induce any observable signs of PAH under basal conditions, 
even though ADMA levels in DDAH KO mice under basal conditions were significantly 
higher than in hypoxic WT mice. This finding indicates that DDAH1 deficiency and 
chronically increased systemic ADMA does not independently induce PAH. The finding 
that DDAH1 KO mice exhibit significantly elevated pulmonary peripheral artery 
muscularization, pulmonary fibrosis, RV pressure, and RV hypertrophy in response to 
hypoxia+SU5416 however, suggests that DDAH1 activity, likely through degradation of 
ADMA and preserving NO signaling, does attenuate PAH induced by additional 
pulmonary stress. While our findings clearly indicate that DDAH1 deletion does not 
induce pulmonary hypertension in the relatively sterile, unstressed, basal conditions of 
this experiment, it seems plausible, based on the exacerbated response to 
hypoxia+SU5416, that chronic DDAH1 deficiency could increase risk of PAH 
development in environmental conditions that introduce more pulmonary stress (i.e. 
environmental toxins, infection, etc). 
 
While the most obvious protective role of DDAH1 is degrading ADMA, DDAH1 has 
demonstrated several ADMA independent effects which could also influence PAH. For 
instance, DDAH1 can promote endothelial cell proliferation through activation of ras and 
Akt (16). Akt activity is also important for eNOS activity (131), so this may be an 
additional mechanism of increasing NO formation. While promoting endothelial cell 
proliferation may help repair damaged endothelium and preserve normal vessel 
architecture in the early stages of this disease, disorganized endothelial cell proliferation 
can also exacerbate PAH progression through formation of plexiform lesions (132). In 
addition, Akt activation promotes smooth muscle cell proliferation that promotes small 
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artery occlusion (133). Thus, ADMA dependent and independent actions of DDAH1 may 
have different impacts on PAH pathology depending upon the cell type involved and 
stage of PAH development.  
 
Because of the important role of NO signaling in attenuating PAH, and because DDAH1 
activity is often reduced in this condition, over-expression of DDAH1 might be expected 
to attenuate PAH. Transgenic DDAH1 over-expressing mice have been produced, and 
these mice exhibit reduced ADMA levels, and lower systemic vascular resistance (39). In 
a 2 week hypoxia-induced PAH model, DDAH1tg mice exhibited less vascular 
remodeling, reversal of pulmonary cGMP reduction, and complete prevention of RV 
hypertrophy (134). A separate study however, demonstrated that while DDAH1tg mice 
exhibited improved vasodilation under hypoxia for 3 hours, PAH development was no 
different from WT mice after 4 weeks hypoxia (135). It is possible that the protective 
effects of increased DDAH1 are only manifested early in the disease, or that other 
factors override the protective effects of DDAH1 over-expression during extended 
hypoxia. Interestingly, our study showed that DDAH1 activity at 3 weeks of 
hypoxia+SU5416 is reduced approximately 30% in WT mice even though DDAH1 
protein levels did not change, indicating the reduced DDAH activity is a result of reduced 
DDAH1 quality. Previous studies have also shown that DDAH1 activity is inhibited post-
translationally by oxidative stress (68) or inflammatory factors (48). Thus, DDAH1 protein 
levels do not necessarily indicate DDAH1 activity, indicating that maintaining DDAH1 
activity as well as DDAH1 expression is likely important for preserving NOS function in 
PAH.   
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Our data showing that lung DDAH1 activity was reduced in WT mice by 
hypoxia+SU5416, and that global (6) or endothelial specific (15) deletion of DDAH1 
increases plasma ADMA levels, supports the concept that a reduction in DDAH1 activity 
contributes to increased ADMA levels. However, plasma ADMA levels were still elevated 
by hypoxia in DDAH1 KO mice, suggesting additional mechanisms also contribute to 
elevated ADMA. Expression of the arginine methyl transferase, PRMT3, was increased 
by hypoxia in both WT and DDAH1 KO mice, and increased arginine methylation may 
result in further amplified ADMA levels in absence of DDAH1 activity. Because ADMA is 
derived from proteolysis of proteins containing methylated arginines, increased protein 
catabolism associated with tissue remodeling may also contribute to increased ADMA. 
There is also evidence that elevations in systemic ADMA contributes to chronic kidney 
disease (45), so renal excretion of ADMA might also be impaired in this model, further 
exacerbating the already elevated plasma ADMA levels. 
In addition to attenuating systemic ADMA accumulation and vascular remodeling in the 
lungs, our data also suggest DDAH1 exerts anti-hypertrophic effects within 
cardiomyocytes, as indicated by the greater hypertrophy observed in cardio-specific 
DDAH1 KO mice under apparently equivalent pulmonary arterial pressures. The specific 
mechanism of DDAH1 protection against cardiomyocyte hypertrophy is currently 
unknown. Based upon previous studies showing protection against pressure overload 
induced LV hypertrophy by sildenafil (99, 136) or tetrahydrobiopterin (137), DDAH1 
removal of cardiomyocyte ADMA might be expected to exert similar anti-hypertrophic 
effects by preserving NO synthesis and cGMP production. Right heart failure is a 
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significant cause of mortality in PAH patients (138), so identifying the specific 
mechanisms by which DDAH1 protects against RV hypertrophy will be important. 
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6. Conclusion 
Novelty and Significance: Increased ADMA levels and reduced DDAH activity are 
associated with several cardiovascular diseases, including pulmonary hypertension, but 
whether these factors cause or contribute to PAH development was not clear.  
What Is New? Global and cardiac specific DDAH1 knockout mice were used to examine 
the impact of DDAH1 in hypoxia+SU5416 induced pulmonary hypertension and right 
ventricular hypertrophy. 
What Is Relevant? Global DDAH1 deletion and chronically increased ADMA did not 
cause PAH under basal conditions, but exacerbated vascular remodeling and PAH 
induced by hypoxia+SU5416. Cardiomyocyte DDAH1 attenuated right ventricular 
hypertrophy without influencing lung remodeling and pulmonary arterial pressure.  
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7. Summary 
Pulmonary arterial hypertension (PAH) is a progressive disease with a very poor 
prognosis. Recent studies have demonstrated that PAH is associated with diminished 
nitric oxide (NO) bioavailability, increased level of endogenous nitric oxide synthase 
(NOS) inhibitor Asymmetric dimethylarginine (ADMA), and decreased lung 
dimethylarginine dimethylaminohydrolse (DDAH) activity. DDAH1 is essential for 
degradation of ADMA and for optimal vascular endothelial nitric oxide production, but the 
impact of DDAH1 in PAH development and subsequent right ventricular (RV) 
hypertrophy is not clear. The objective of this study is to determine the impact of global 
DDAH1 gene knockout (KO) and cardiomyocyte restricted DDAH1 gene KO (Cardio-
DDAH1 KO) on hypoxia+SU5416 induced PAH development and RV hypertrophy. 
 
Chronic hypoxia and SU5416 result in reduced lung DDAH activity, increased circulating 
ADMA content, and PAH in wild type mice. Using global DDAH1 KO mice, we 
demonstrate that DDAH1 KO increases lung and circulating ADMA levels, but this does 
not cause PAH development in mice under control conditions. However, DDAH1 KO 
significantly exacerbates chronic hypoxia+SU5416-induced PAH, as indicated by 
significantly increased RV pressure, more RV hypertrophy, and enhanced pulmonary 
vascular remodeling in DDAH1 KO mice as compared to wild type mice. In addition, 
cardiomyocyte specific DDAH1 KO did not exacerbate hypoxia+SU5416-induced 
increases in RV pressure or lung vascular remodeling, but significant exacerbated 
hypoxia+SU5416-induced RV hypertrophy in comparison to wild type littermates, 
indicating that DDAH1 distributed in cardiomyocytes protects against RV hypertrophy 
independent of increased pulmonary artery pressure. 
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Collectively, our data indicate that DDAH1 plays an important role in protection against 
hypoxia+SU5416-induced PAH and RV hypertrophy by attenuating maladaptive 
pulmonary remodeling and through cardiomyocyte specific anti-hypertrophic effects in 
the heart.   
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CHAPTER 2 
Effect of adenosine monophosphate-activated protein kinase 
(AMPK) alpha 2 gene deletion on pulmonary arterial 
hypertension in mice 
 
1. Introduction 
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by 
progressively increasing pulmonary vascular resistance, right heart failure and death. 
Increased lung vascular smooth muscle cell (VSMC) growth and proliferation is a key 
cellular event that leads to pathological pulmonary vascular remodeling and right 
ventricular hypertrophy or failure.  
 
Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric protein 
complex consisting of a catalytic subunit α (either α1 or α2), and 2 regulatory subunits (β 
and γ).  In response to increased cellular AMP content under metabolic or other stress 
conditions, AMPK is quickly activated to maintain cellular energy homeostasis (139, 
140). AMPK activation reduces energy-consuming processes such as protein translation 
by inhibiting the mTOR signaling pathway and increasing energy production by 
enhancing glucose uptake and glycolysis etc (139, 140).  Recent studies indicate that 
AMPK activation may play an important role in attenuating PAH and right ventricular 
hypertrophy. Igata et al reported that 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR), an activator of AMPK, inhibits human VSMC proliferation (141). AMPK 
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activation was also shown to inhibit rat VSMC proliferation (142) and limit VSMC protein 
synthesis under conditions of thromboxane receptor activation (143). In addition, a 
recent study suggests that mTOR complex 2 promotes VSMC proliferation and survival 
in part through down-regulation of AMPK (144). While AMPKα1 appears to be the 
dominant catalytic isoform in smooth muscle cells, several recent studies demonstrated 
that AMPKα2 (but not AMPKα1) plays the essential role in attenuating vascular smooth 
muscle cell growth and proliferation (145, 146). Moreover, studies have demonstrated 
that activation of AMPK is important in attenuating cardiac hypertrophy and heart failure 
development (147-152). Our previous studies have demonstrated that AMPKα2 plays an 
important role in attenuating cardiomyocyte hypertrophy and left ventricular failure (147, 
150, 151). 
 
Based on the findings that AMPKα2 attenuates VSMC proliferation and cardiomyocyte 
hypertrophy (145-148), we reasoned that AMPKα2 might play a role in attenuating 
hypoxia-induced PAH and right ventricular hypertrophy. Consequently, the effect of 
AMPKα2 gene knockout on hypoxia induced PAH in mice was studied.     
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2. Materials and Methods 
AMPKα2 knockout  (KO) mice 
AMPK α2 mice and control wild type mice used in the present study are described 
previously (147, 150 153).  This study was approved by the Institutional Animal Care and 
Use Committee of University of Minnesota. 
Hypoxia and Sugen5416-induced PAH in mice 
Male mice ages 3-5 months were exposed to hypobaric hypoxia (154). Briefly, the 
pressure in the hypobaric chamber was decreased progressively from 0.8 atm (16.9% 
oxygen) on day 1 to 0.5 atm (10.5% oxygen) after day 7 for adaptation and was 
maintained at 10.5% oxygen for 2 more weeks as illustrated in Figure 1A. The chamber 
was opened once every week for cleaning, feeding, and injection. The mice in the 
hypoxia group received subcutaneous weekly injection of Sugen-5416 (25mg/kg, R&D 
Systems) (155). After hypoxic exposure for total 3 weeks, determination of RV pressure 
and hypertrophy was performed as described. The mice in sham group were kept in 
normobaric conditions for 3 weeks. 
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Measurements of RV hemodynamics 
At the end of the study protocol, mice were anesthetized with 2% isoflurane. Mice were 
intubated with a 20-gauge Teflon tube attached to a MiniVent type 845 mouse ventilator 
(Hugo Sachs Elektronik) (ventilator settings: breathing frequency, 80 breaths per minute; 
pressures, 9/0 cm H2O; inspiratory/expiratory ratio, 1:1). RV hemodynamics were 
determined at open-chest by a 1.2-F pressure catheter (Scisense Inc, Ontario Canada) 
(156, 157).    
Sample Preparation 
After the final hemodynamic assessment, the mice were euthanized by exsanguination. 
Before sample collection, the lungs were perfused with 6 ml of Calcium and magnesium 
free phosphate buffered saline through the right ventricle. The upper right lobe of lung 
was inflated through the trachea and then fixed in 10% buffered formalin for histological 
analysis. The other lung tissue was harvested and stored in -80°C freezer for 
biochemical analysis. The wet weights of RV and left ventricle (LV) + septum (S) were 
weighed and the ratios of RV weight to LV + S were determined (157)  
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Histological staining, evaluation of lung vascular muscularization, lung   
fibrosis and RV fibrosis 
For histological staining, tissues were sectioned to 5μm. The relative pulmonary vascular 
muscularization was determined by H&E staining. Briefly, 60 intra-acinar arteries (50-
200 µm) were examined per mouse. Intra-acinar arteries with a complete medial coat of 
muscle were categorized as Fully Muscular (FM) arteries.  Intra-acinar arteries with only 
a crescent of muscle were defined as partially muscular (PM) arteries.  Intra-acinar 
arteries with no apparent muscle were defined as nonmuscular (NM) arteries as 
previously described (155, 157).   
RV sections were stained with Sirius Red (Sigma) for detection of fibrosis. Lung fibrosis 
was stained using Modified Masson’s Trichrome Stain Kit (Scy Tek laboratories). The 
percent volume fibrosis for lung and ventricular fibrosis was determined using the 
method described previously (156, 158). Lung sections were also stained with 
monoclonal antibody to identify leucocytes using an antibody against CD45. Briefly, 
tissue sections were deparaffinized and rehydrated in PBS. The sections were incubated 
with 3% H2O2 in PBS for 20 minutes, followed by 3% BSA solution for 1 hour. Sections 
were then incubated with corresponding monoclonal primary antibody (1:400) overnight 
at 4oC, followed by incubation with avidin/biotin peroxidase-linked secondary antibody 
(1:1000) (Invitrogen). Staining was visualized using an avidin/biotin peroxidase-linked 
detection system (Vector Laboratories, Burlingame, CA). 
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Western Blots and Chemical Analysis 
Protein extracts from different groups of lung were fractionated on a polyacrylamide gel, 
transferred to nitrocellulose membranes, and probed with various antibodies. Total 
AMPK activity of lung tissues was measured as previously described (147). 
Data and Statistical Analysis 
All values were expressed as mean ± standard error. Data from two groups was 
compared with an unpaired t-test.  Two-way ANOVA was used to test for differences 
between KO and wild type animals under sham conditions and after hypoxia+SU5416-
induced PAH. Post hoc pairwise comparisons were made using the Fisher least 
significant difference test. Statistical significance was defined as p<0.05. 
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3. Results 
AMPKa2 KO had no detectable effect on RV pressure and RV hypertrophy 
The bodyweight was monitored weekly as presented in Figure 1B. The result indicates 
that hypoxia caused a significant but similar reduction of bodyweight in both wild type 
and AMPKa2 KO mice. We assessed RV pressure as a surrogate of the pulmonary 
arterial pressure in each group. RV systolic pressure, RV end-diastolic pressure, RV 
dp/dtmax, RV dp/dtmin and heart rate were not different between AMPKa2 KO mice 
and wild type controls under sham conditions (Figure 1C-H). AMPKa2 KO also had no 
detectable effect on RV hypertrophy under sham conditions as indicated by the similar 
ratio of RV weight to LV (LV+ septum) weight between AMPKa2 KO mice and wild type 
mice, as well as comparable RV weight, and RV weight ratios to bodyweight, or tibial 
length (Figure 2B,).  
 AMPKa2 KO aggravated the hypoxia+SU5416-induced increase of RV pressure 
Interestingly, AMPKa2 KO significantly exacerbated hypoxia-induced increases of RV 
systolic pressure (Figure 1D), RV dp/dtmax, (Figure 1F), and RV dp/dtmin (Figure 1G). 
AMPKa2 KO did not affect RV diastolic pressure and heart rate in mice after chronic 
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D E F G H
2-WAY ANOVA
Hypoxia+SU5416             p=0.06
KO                                     p=0.14
Hypoxia+SU5416 × KO   p=0.48
2-WAY ANOVA
Hypoxia+SU5416             p<0.01
KO                                     p=0.01
Hypoxia+SU5416 × KO   p<0.05
2-WAY ANOVA
Hypoxia+SU5416             p<0.01
KO                                     p=0.07
Hypoxia+SU5416 × KO   p=0.14
2-WAY ANOVA
Hypoxia+SU5416             p>0.05
KO                                     p>0.05
Hypoxia+SU5416 × KO    p>0.05













Hypoxia+SU5416             p<0.01
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Figure 1. AMPKα2 knockout aggravated the hypoxia+SU5416-induced increase of RV 
pressure. Wild type or AMPKα2 KO mice were exposed to normoxic conditions or 
hypoxia+SU5416 treatment for 3 weeks (A), and the change (%) of body weight were 
determined (B). RV pressure measurements were obtained by catheterization of the 
right ventricle. Reprentative RV pressure tracings from wild type and AMPK α2 KO mice 
exposed to sham or hypoxia+SU5416 conditions are shown in (C) Right ventricular 
systolic pressure (D), right ventricular end-diastolic pressure (E), right ventricular 
dp/dtmax (F), right ventricular dp/dtmin (G), heart rate (H) were calculated from 7-9 mice 
in each group. * indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates 
p<.05 comparing WT to KO. 
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AMPKa2 KO exacerbated the hypoxia+SU5416-induced increase of RV 
hypertrophy and fibrosis 
Consistent with the greater increase of RV systolic pressure in AMPKa2 KO mice after 
hypoxia+SU5416, AMPKa2 KO mice exhibited greater increase in RV to body weight 
ratio (1.45 ± 0.06mg/g in wild type hypoxia+SU5416 group versus 1.72 ± 0.07mg/g in 
KO hypoxia+SU5416 group; p<0.05) (Figure 2A) and RV to LV + septum ratio (0.39 ± 
0.01 in wild type hypoxia+SU5416 versus 0.45 ± 0.02 in KO hypoxia+SU5416; p<0.05) 
(Figure 2B) after hypoxia+SU5416, indicating that AMPKa2 KO exacerbated hypoxia-
induced RV hypertrophy. Histological analysis indicated that hypoxia increased RV 
fibrosis to a greater degree in AMPKa2 KO mice compared to wild type mice (5.67 ± 
0.54 % in wild type mice versus 7.35 ± 0.43 % in AMPKa2 KO mice; p<0.05)  (Figure 2E 
and F). 















































































































































Hypoxia+SU5416               p<0.01
KO                                       p<0.01
Hypoxia+SU5416 × KO      p<0.01
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p<0.01
Hypoxia+SU5416 × KO     p=0.01
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p<0.01
Hypoxia+SU5416 × KO     p=0.02
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p=0.34
Hypoxia+SU5416 × KO     p=0.22
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p>0.05



















































































Figure 2. AMPKα2 KO exacerbated the hypoxia+SU5416-induced increase of RV 
hypertrophy and fibrosis. After 3 week exposure to hypoxic+SU5416 or sham conditions, 
hearts and lungs were collected. Right ventricle weight to body weight ratio (A), right 
ventricle weight to left ventricle + septum weight  (B), left ventricle weight septum to body 
weight ratio (C), and lung weight to body weight ratio (D). For analysis of right ventricular 
fibrosis, right ventricular tissue was fixed and stained with Sirius red reagent (E). Percent 
fibrotic tissue was calculated from 5 samples in each group (F). * indicates p<0.05 
comparing hypoxia+SU5416 to sham. # indicates p<.05 comparing WT to KO. 
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AMPKa2 KO exacerbated hypoxia+SU5416-induced pulmonary vascular 
remodeling 
To determine the effect of AMPKa2 KO on pulmonary vascular remodeling, we 
determined the percentage of non-muscularized (NM), partially muscularized (PM), and 
fully muscularized small arteries (FM) in wild type mice and AMPKa2 KO mice under 
sham conditions and 3 weeks after hypoxia+SU5416 (Figure 3A and B). Under control 
conditions, the percentage of nonmuscularized, partially muscularized and fully 
muscularized small arteries in lung tissues was not different between wild type mice and 
AMPKa2 KO mice (Figure 3A and B). Exposure to hypoxia+SU5416 caused increases 
in fully muscularized small arteries in wild type and AMPKa2 KO mice (Figure 3B).  The 
increases were greater in the AMPKa2 KO mice (p< 0.05)(Figure 3B). As expected, 
hypoxia also resulted in decreased non-muscularized small arteries in wild type and 
AMPKa2 KO mice (Figure 3B). Again, the loss of non-muscularized small arteries was 
greater in AMPKa2 KO mice (p < 0.05)(Figure 3B).  












































































Figure 3. AMPKα2 KO exacerbated hypoxia+SU5416-induced pulmonary vascular 
remodeling and fibrosis. Lungs from wild type and AMPKα2 KO mice exposed to sham 
or hypoxia+SU5416 conditions were flushed, fixed in formalin, and stained using eosin-
hemotoxylin for analysis of pulmonary vessel muscularization. Representative images 
are shown in (A) and average percent of non-muscularized, partially muscularized, and 
completely muscularized pulmonary arterioles were calculated from 5 samples in each 
group (B). * indicates p<0.05 comparing hypoxia+SU5416 to control. # indicates p<.05 
comparing WT to KO. 
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AMPKa2 KO significantly exacerbated the hypoxia+SU5416-induced lung fibrosis 
Fibrosis was detected by Masson trichrome staining under sham conditions and 3 
weeks post hypoxia+SU5416. Lung fibrosis was comparable between AMPKa2 KO 
mice and wild type under sham conditions. Hypoxia+SU5416 caused lung fibrosis in 
both wild type mice and AMPKa2 KO mice, but the increase was significantly greater in 
the AMPKa2 KO mice than in the wild type mice (p < 0.05) (Figure 4A and B). In 
addition, Western blotting showed that hypoxia+SU5416 caused significantly more 
increase of lung collagen-III protein content in AMPKa2 KO mice than in wild type mice 
(Figure 4C and D).  









































































Hypoxia+SU5416               p<0.01
KO                                       p<0.01
Hypoxia+SU5416 × KO     p<0.01
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p<0.01






































Figure 4. AMPKα2 KO exacerbated the hypoxia+SU5416-induced lung fibrosis. Lungs 
from wild type and AMPKα2 KO exposed to sham or hypoxia+SU5416 conditions were 
collected and fixed and analyzed for fibrosis using Trichrome stain. Representative 
images are shown in (A). Average percent lung fibrosis was calculated (B). Lungs were 
also analyzed by western blot for expression of type III collagen or vinculin (as a loading 
control) (D). Expression levels of the indicated proteins were analyzed by densitometry 
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from 5 animals in each group (C). * indicates p<0.05 comparing hypoxia+SU5416 to 
sham. # indicates p<.05 comparing WT to KO. 
 
AMPKa2 KO exacerbated hypoxia+SU5416-induced pulmonary inflammation and 
increased lung VCAM-1 expression 
Histological analysis did not reveal any noticeable increase of lung leukocyte infiltration 
in AMPKa2 KO mice under sham condition. Hypoxia+SU5416 caused lung leucocyte 
accumulation (as indicated by the staining of CD45) in both wild type mice and AMPKa2 
KO mice, but the increase was significant greater in the AMPKa2 KO mice than in the 
wild type mice (Figure 5A and C), suggesting AMPKa2 plays a role in limiting 
hypoxia+SU5416-induced pulmonary inflammation.  




























































WT Sham WT Hypoxia+SU5416KO Sham KO Hypoxia+SU5416
2-WAY ANOVA
Hypoxia+SU5416               p=0.05
KO                                       p<0.01
Hypoxia+SU5416 × KO     p=0.36
2-WAY ANOVA
Hypoxia+SU5416               p=0.01
KO                                       p=0.03

































Figure 5. AMPKα2 KO exacerbated hypoxia+SU5416-induced pulmonary inflammation. 
Lungs from wild type and AMPKα2 KO exposed to sham or hypoxia+SU5416 conditions 
were collected and fixed and stained CD45 for leucocytes. Representative images are 
shown in (A). Count of leucocytes was calculated (C). Lungs were also analyzed by 
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western blot for expression of VCAM-1 (vinculin as a loading control) (D). Expression 
levels of VCAM-1 were analyzed by densitometry (C). * indicates p<0.05 comparing 
hypoxia+SU5416 to sham.  
 
Effect of AMPKa2 KO on lung AMPK activity 
Western blot showed that AMPKa2 KO abolished lung AMPKa2 expression as 
expected. Interestingly, AMPKa2 KO resulted in up-regulation of lung AMPKa1 
expression under both sham conditions and after hypoxia+SU5416. Hypoxia+SU5416 
caused no change of lung AMPKa2 expression in wild type mice but significant 
increased lung AMPKa1 expression in both wild type and AMPKa2 KO mice (Figure 6A 
– C), consistent with the notion that AMPKa1 is highly inducible (9). Total AMPK activity 
was also determined (Figure 6D).  To our surprise, lung AMPK activity did not decrease, 
but significantly increased in AMPKa2 KO mice under both sham conditions and after 
hypoxia+SU5416 (Figure 6D), suggesting increased AMPKa1 can maintain and even 
increase overall AMPK activity in absence of AMPKa2.   
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B C D2-WAY ANOVA
Hypoxia+SU5416               p=0.01
KO                                       p=0.05
Hypoxia+SU5416 × KO     p=0.31
2-WAY ANOVA
Hypoxia+SU5416               p=0.10
KO                                       p<0.05

































Figure 6. AMPK α2 KO did not decrease lung AMPK activity. Lungs from wild type and 
AMPKα2 KO exposed to sham or hypoxia+SU5416 conditions were collected and 
analyzed by western blot for expression of AMPKα2, AMPKα1 and vinculin (A). 
Expression levels of the indicated proteins were analyzed by densitometry (B and C). 
Total AMPK kinase activity was measured by immuno-precipitation of AMPK from lung 
lysates and incorporation of radioactivity from [32P]ATP into SAMs peptide (D) (n=5 each 
group). * indicates p<0.05 comparing hypoxia+SU5416 to sham. # indicates p<.05 
comparing WT to KO. 
  118 
AMPKa2 KO significantly increased lung p70S6K and p-S6. 
Because previous studies demonstrated that AMPK regulates activity of the p70SK/S6 
signaling pathway that drives smooth muscle and cardiomyocyte hypertrophy, we further 
determined the expressions of total and phosphorylated p70S6K and S6 in lung tissues. 
The results showed that hypoxia+SU5416 caused significant increases of lung p-70S6K 
and p-S6 protein in AMPKa2 KO mice (Figure 7A - C). 
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Hypoxia+SU5416               p<0.01
KO                                       p<0.05
Hypoxia+SU5416 × KO     p<0.05
2-WAY ANOVA
Hypoxia+SU5416               p<0.01
KO                                       p<0.01


























Figure 7. AMPKα2 KO up regulated phosphorylation of pulmonary mTOR complex 1 and 
its downstream targets in mice after hypoxia+SU5416. Lungs from wild type and 
AMPKα2 KO exposed to sham or hypoxia+SU5416 conditions were collected and 
analyzed by western blot for phosphorylated and total p70S6k, and S6 ribosomal protein, 
as well as vinculin as a loading control (A). Expression levels of the indicated proteins 
were analyzed by densitometry (B and C). * indicates p<0.05 comparing 
hypoxia+SU5416 to control. # indicates p<.05 comparing WT to KO. 
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4. Discussion 
This study demonstrates for the first time that AMPKa2 plays an important role in 
attenuating development of PAH and right ventricular hypertrophy, at least in the 
Sugen/hypoxia model. Our data indicate that genetic disruption of AMPKa2 has no 
observable influence on pulmonary structure or right ventricular hemodynamics under 
basal conditions, but significantly exacerbates muscularization of pulmonary arteries, 
lung fibrosis, and pulmonary vascular resistance (as indicated by increased RV 
pressure) in response to hypoxia+SU5416. The development of PAH in AMPKa2 KO 
mice was associated with significant up-regulation of lung p70S6k activity, as well as 
increased expression of VCAM-1. This suggests that deletion of AMPKa2 promotes pro-
growth and inflammatory signaling pathways. The maladaptive response to 
hypoxia+SU5416 in AMPKa2 KO mice occurred despite up-regulation of AMPKa1 and 
increased overall levels of AMPK activity. This suggests that AMPKa2 protects against 
the development of PAH independent of the total lung AMPK activity.  
Pulmonary arterial hypertension is associated with pulmonary VSMC proliferation.  
Recent evidence suggests that VSMC proliferation is regulated by AMPK. For example, 
AMPK activation was shown to inhibit growth factor-induced VSMC proliferation through 
up-regulation of cell cycle inhibitors (141, 142), and block cell migration by preserving 
expression of cell-cell adhesion molecule cadherin (145). In addition, there is evidence 
that mTOR signaling, which is inhibited by AMPK, plays an important role in hypoxia and 
growth factor-induced VSMC proliferation (157, 158). We report that AMPKa2 disruption 
up-regulates phosphorylation of pulmonary mTOR complex 1 targets p70s6kThr389, up-
regulates phosphorylation of ribosomal protein S6Ser235, and increases pulmonary 
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arteriole muscularization in response to hypoxia+SU5416. This is consistent with a role 
for AMPKa2 in limiting VSMC proliferation, in part, by down-regulating mTOR activity.   
AMPKa2 may also play a direct role in limiting lung inflammation. We found that VCAM-
1 expression is elevated in AMPKa2 KO lungs under basal conditions and even further 
up-regulated in response to hypoxia+SU5416. VCAM-1 is a cell adhesion molecule 
expressed on vascular endothelial cells, usually in response to inflammatory cytokines 
such as TNFα and Il-1β. VCAM-1 promotes tight adhesion of leukocytes to the vessel 
wall, and plays an important role in recruitment of circulating monocytes to sites of tissue 
injury. In hypoxia+SU5416-induced PAH, a prolonged inflammatory response appears 
mostly as a consequence of a pro-inflammatory microenvironment within and 
surrounding the pulmonary arteries (159). While increased VCAM-1 expression in 
AMPKa2 KO lungs did not cause an observable influx of leucocytes under basal 
conditions, pulmonary vessels of AMPKa2 KO mice appear to be predisposed to 
increased leukocyte adhesion during hypoxic stress, as suggested by the high number 
of CD45 positive cells observed in AMPKa2 KO lungs after exposure to 
hypoxia+SU5416. In further support of AMPK regulation of vascular inflammation, 
metformin, an activator of AMPK, down-regulated activity of the inflammatory mediator 
NF-κβ (160) and reduced VCAM expression in endothelial cells (161). 
AMPKa2 KO also exacerbated pulmonary fibrosis in response to hypoxia+SU5416. This 
finding can be interpreted together with the observation that VCAM-1 expression was 
elevated under basal conditions and that fibrosis in the lung was most evident 
surrounding pulmonary vessels. It implies that AMPKa2 disruption promotes a 
proliferative, pro-inflammatory micro-environment in and around the pulmonary 
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vasculature, that may elevate basal fibroblast proliferation or collagen synthesis. It is 
also possible that increased VCAM-1 expression in AMPKa2 KO promotes the 
recruitment of recently described monocyte-derived mesenchymal cells that synthesize 
collagen and contribute to vascular remodeling in hypoxia (162, 163). The increased 
collagen synthesis and VCAM-1 expression in AMPKa2 KO mice under control 
conditions suggests that these mice may be predisposed to vascular remodeling and 
fibrosis of PAH in response to additional stress, such as Sugen/hypoxia.  
The greater development of PAH in AMPKa2 KO mice, despite increased AMPKa1 
expression and no reduction of overall AMPK activity suggests AMPKa2 plays a critical 
role in adaptation to hypoxic stress that is not compensated for by increased AMPKa1 
expression. While puzzling at first glance, these findings are consistent with recent 
studies identifying a specific role for AMPKa2, but not AMPKa1, in VSMC proliferation 
and vascular remodeling. For instance, Song et al. demonstrated that while AMPKa1 
accounts for approximately 90% of total AMPKa subunits in mouse VSMCs, deletion of 
AMPKa2, but not AMPKa1 reduced expression of the cell cycle inhibitor p27 and 
enhanced VSMC proliferation8. AMPKa2 KO but not AMPKa1 KO, also promoted VSMC 
migration (145). On the other hand, AMPKa1 has distinct roles compared to AMPKa2 in 
myogenesis (168), regulation of the cystic fibrosis transmembrane conductance 
regulator in epithelial cells (169), and targeting Na/K-ATPase endocytosis in response to 
hypoxia (170). Thus, AMPKa1 and AMPKa2 likely exhibit both distinct and overlapping 
functions. Our findings demonstrate for the first time that AMPKa2 plays an important 
role in attenuating Sugen/hypoxia-induced PAH. 
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Not surprisingly, hypoxia+SU5416-induced RV hypertrophy was exacerbated in 
AMPKa2 KO mice.  Increased RV hypertrophy in the AMPKa2 KO mice is likely due not 
only to increased RV systolic afterload caused by worse PAH, but also may be attributed 
to loss of the anti-hypertrophic influence of AMPKa2 in cardiomyocytes. Indeed, our 
previous study demonstrated that AMPKa2 KO mice exhibit elevated mTORC1 signaling 
and develop greater hypertrophy and heart failure in response to the same systolic  
pressure overload as compared to wild type mice (147). AMPK also attenuated 
phenylephrine-induced cardiomyocyte hypertrophy in vitro (152). While our combined 
studies indicate AMPKa2 not only attenuates RV hypertrophy through reducing afterload 
(by decreased lung vascular remodeling) and direct attenuated cardiomyoycte 
hypertrophy, we are unable to determine how much the increased right ventricular 
hypertrophy in AMPKa2 KO mice can be attributed to increased pulmonary vascular 
resistance or to increased sensitivity of cardiomyocytes to hypertrophic stimuli. In 
addition, while evidence suggests that AMPKa2 KO promotes VSMC proliferation, a key 
event in development of PAH, the involvement and cooperation of multiple cell types in 
progression of PAH make it difficult to identify which specific cellular response (i.e. 
VSMC proliferation, inflammation, fibrosis) aggravated by AMPKa2 disruption is most 
responsible for exacerbating PAH in global AMPKa2 KO mice.  
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5. Conclusion 
What Is New?  
AMPKa2 knockout exacerbated hypoxia+SU5416-induced pulmonary hypertension, lung 
vascular remodeling and right ventricular hypertrophy in mice. This protective role of 
AMPKα2 against pulmonary hypertension appears independent of total lung AMPK 
activity.  
What Is Relevant? 
This study demonstrates that proper AMPKa2 signaling is important in protecting 
against hypoxia+SU5416-induced pulmonary hypertension, lung vascular remodeling 
and right ventricular hypertrophy.  
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6. Summary 
 Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and 
right ventricular hypertrophy. Adenosine monophosphate kinase alpha 2 subunit 
(AMPKα2) protects against vascular remodeling and cardiac hypertrophy, yet the role of 
AMPKα2 in the development of PAH is unclear. Here we examined the role of AMPKα2 
in Sugen/hypoxia-induced PAH in mice utilizing an AMPKα2 knockout (KO) mouse 
strain. Under normoxic conditions, AMPKα2 KO had no observable effect on pulmonary 
vascular remodeling, right ventricular pressure, or right ventricular hypertrophy in 
comparison to wild type mice. However, in response to hypoxia plus VEGF antagonist 
Sugen-5416, AMPKα2 KO mice exhibited increased vascular remodeling (i.e. 
muscularization of small pulmonary arteries), leucocyte infiltration, pulmonary fibrosis, 
and right ventricular pressure, leading to increased right ventricular hypertrophy. The 
impaired ability of AMPKα2 KO mice to adapt to hypoxic stress was associated with 
increased phosphorylation of mTORC1 targets p70S6 kinaseThr389 and S6 ribosomal 
proteinSer235, as well as increased expression of Vascular Cell Adhesion Molecule-1 
(VCAM-1). Surprisingly, disruption of AMPKα2 did not result in a significant loss in 
overall AMPK activity, which was partially compensated for by increased AMPKα1 
expression. Our data indicate that AMPKα2 attenuates hypoxia-induced pulmonary 
hypertension, in part by reducing mTORC1 signaling and leukocyte recruitment. This 
protective role of AMPKα2 against PAH appears independent of the AMPK activity.  
  126 
References 
1. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for 
clinicians: new concepts and experimental therapies. Circulation. 2010;121(18):2045-
2066. 
2. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, 
Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and 
molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20-
31. 
3. Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM. 
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 
2005;111(16):2126-2133. 
4. Stasch JP, Evgenov OV. Soluble quanylate cyclase stimulators in pulmonary 
hypertension. Handb Exp Pharmacol. 2013;218:279-313. 
5. Preston IF, Suissa S, Humbert M. New perspectives in long-term outcomes in clinical 
trials of pulmonary arterial hypertension. Eur Respir Rev. 2013;22(130):495-502. 
6. Hu X, Atzler D, Xu X, Zhang P, Guo H, Lu Z, Fassett J, Schwedhelm E, Boger RH, 
Bache RJ, Chen Y. Dimethhylarginine dimethylaminohydrolase-1 is the critical 
enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. 
Arterioscler Thromb Vasc Biol. 2011;31(7):1540-1546. 
7. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA. Evidence for 
dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-
induced pulmonary hypertension. Circulation. 2003;108:1493-1498. 
8. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide 
synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase 
  127 
activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol lung Cell 
Mol physiol. 2007;292:L1480-1487. 
9. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, 
Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial 
hypertension. Arterioscler Thromb Vasc Biol. 2005;25:1414-1418. 
10. Boger RH. The emerging role of asymmetric dimethylarginine as a novel 
cardiovascular risk factor. Cardiovasc Res. 2003;59:824-833. 
11. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct 
conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res 
Commun. 1987;148:671-677. 
12. Ding H, Wu B, Wang H, Lu Z, Yan J, Wang X, Shaffer JR, Hui R, Wang DW. A novel 
loss-of-function DDAH1 promoter polymorphism is associated with increased 
susceptibility to thrombosis stroke and coronary heart disease. Circ Res. 
2010;106:1145-1152. 
13. Valkonen V-P, Tuomainen T-P, Laaksonen R. DDAH gene and cardiovascular risk. 
Vasc Med. 2005;10:S45-S48. 
14. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, 
Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases 
with distinct tissue distributions and homology with microbial arginine deiminases. 
Biochem J. 1999;343:209-214. 
15. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, Chen J, Schwedhelm E, Luneburg N, Boger 
RH, Zhang P, Chen Y. Vascular endothelial-specific dimethylarginine 
dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an 
important role in removing asymmetric dimethylarginine. Circulation. 2009;120:2222-
2229. 
  128 
16. Zhang P, Hu X, Xu X, Chen Y, Bache RJ. Dimethylarginine dimethylaminohydrolase 
1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler Thromb 
Vasc Biol. 2011;31:890-897. 
17. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric 
dimethylarginines is regulated in the lung developmentally and with pulmonary 
hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195-1201. 
18. Gray GA, Patrizio M, Sherry L, Miller AA, Malaki M, Wallace AF, Leiper JM, Vallance 
P. Immunolocalisation and activity of DDAH I and II in the heart and modification post-
myocardial infarction. Acta Histochem. 2010;112:413-423. 
19. Hu T, Chouinard M, Cox AL, et al. Farnesoid X receptor agonist reduces serum 
asymmetric dimethylarginine levels through hepatic dimethylarginine 
dimethylaminohydrolase-1 gene regulation. J Biol Chem. 2006;281:39831-8. 
20. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: 
report of a National Heart, Lung, and Blood Institute working group on cellular and 
molecular mechanisms of right heart failure. Circulation. 2006;114:1883-91. 
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers 
on survivial in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81 
22. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers 
in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-11. 
23. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and 
translational research “Work in progress.” Circulation. 2000;102:2781-91. 
24. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its 
pathophysiologic regulation. Vascul Pharmacol. 2008;49:134-140.  
  129 
25. Mandegar M, Fung YC, Huang W, Remillard DV, Rubin LJ, Yuan JX. Cellular and 
molecular mechanisms of pulmonary vascular remodeling: role in the development of 
pulmonary hypertension. Microvasc. Res. 2004;68:75-103. 
26. Furchgott RF. Studies on endothelium-dependent vasodilation and the endothelium-
derived relaxing factor. Acta Physiol Scand 1990;139:257-70. 
27. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation 
of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6. 
28. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric 
oxide from L-arginine. Nature 1988:333:664-6. 
29. Moncada S. The L-arginine: nitric oxide pathway. Acta Physiol Scand 1992;145:201-
227. 
30. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on 
hypotension patients with septic shock. Lancet 1991;338:1557-1558. 
31. Vallance P, Moncada S. Role of endogenous nitric oxide in septic shock. New Horiz 
1993;1:77-86. 
32. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+ 
independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-
80. 
33. Belder AJ, Radomski MW, Why HJF, et al. Nitric oxide synthase activities in human 
myocardium. Lancet 1993;341:84-5. 
34. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in 
endotoxin shock. Cardiovasc Res 1992;26:48-57. 
35. Boerth NJ, Dey NB, Cornwell TL Lincoln TM. Cyclic GMP-dependent protein kinase 
regulates vascular smooth muscle cell phenotype. J Vasc Res 1997;34:245-259. 
  130 
36. Cooke JP, Ghebremariam YT. Dietary nitrate, nitric oxide and restenosis. J Clin 
Invest. 2011;121(4):1258-1260. 
37. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit 
synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS 
Lett 1994;356:295-298. 
38. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: 
results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-30. 
39. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase 
regulates nitric oxide synthesis. Circulation 2003;108:3042-3047. 
40. McBride AD, Sliver PA. State of the Arg: protein methylation at arginine comes of 
age. Cell 2001;106:1-10. 
41. Boisvert FM, Cote J, Boulanger MC, Richard S. Aproteomic analysis of arginine-
methylated protein complexes, Mol Cell Proteomics 2003;2:1319-1330. 
42. Wada K, Inoue K, Hagiwara M. Identification of methylated proteins by protein 
arginine N-methyltransferase 1, PRMT1, with a new expression cloning strategy. 
Biochim Biophys Acta 2002;1591:1-10. 
43. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of DDAH and                         
PRMT isoforms in the diabetic rat kidney; effects of angiotensin II receptor blocker. 
Diabetes. 2007;57:172-180. 
44. Achan V, Broadhead M. Malaki M, et al. Asymmetric dimethylarginine causes 
hypertension and cardiac dysfunction in humans and is actively metabolized by 
dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 
2003;23:1455-1459. 
45. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of 
nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575. 
  131 
46. Murray-Rust J, Leiper JM, McAlister M, et al. Structural insights into the hydrolysis of 
cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. 
Nat Struct Biol 2001;8:679-683. 
47. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human 
dimethylarginine dimethylaminohydrolases with distinct tissue distributions and 
homology with microbial arginine deiminases. Biochem J 1999;343:209-214. 
48. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: 
dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-
3095. 
49. Leiper J, Vallance P. Biological significance of endogenous methylarginines that 
inhibit nitric oxide synthases. Cardiovasc Res. 1999;43(3):542-548. 
50. Lee Y, Stallcup M. Minireview: protein arginine methylation of nonhistone proteins in 
transcriptional regulation. Mol Endocrinol 2009;23:425-433. 
51. Bedford MT, Richard S. Arginine methylartion an emerging regulator of protein 
function. Mol Cell 2005;18:263-272. 
52. Boulanger MC, Liang C, Russell RS, Lin R, Bedford MT, Wainberg MA, Richard S. 
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene 
expression. J Virol 2005;79:124-131. 
53. Najbauer J, Johnson BA, Young AL, Aswad DW. Peptides with sequences similar to 
glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized 
by methyltransferase(s) modifying arginine in numerous proteins. J Biol Chem 
1993;268:10501-10509. 
54. Cheng D, Cote J, Shaaban S, Bedford MT. The arginine methyltransferase CARM1 
regulates the coupling of transcription and mRNA processing. Mol Cell 2007;25:71-83. 
  132 
55. Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 is a histone arginine demethylase. 
Science 2007;318:444-447. 
56. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, 
McDonald CH, Cook RG, Bou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD, 
Coonrod SA. Human PAD4 regulates histone arginine methylation levels via 
demethylimination. Science 2004’306:279-283. 
57. Shi Y, Lan C, Matson C, Mulligan P, Wheststine JR, Cole PA, Casero RA, Shi Y 
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 
2004;119:941-953. 
58. Scorilas A, Black MH, Talieri M, Diamandis EP. Genomic organization, physical 
mapping, and expression analysis of the human protein arginine methyltransferase 1 
gene. Biochem Biophys Res Commun 2000;278:349-359. 
59. Pawlak MR, Scherer CA, Chen J, Roshon MJ, Ruley HE. Arginine N-
methyltransferase 1 is required for early postimplantation mouse development, but 
cells deficient in the enzyme are viable. Mol Cell Biol 2000;20:4859-4869. 
60. Yadav N, Lee J, Kim J, Chen J, Hu MC, Aldaz CM, Bedford MT. Specific protein 
methylation defets and gene expression perturbations in coactivator associated 
arginine methyltransferase 1 deficient mice. Proc Natl Acad Sci 2003;100:6464-6468. 
61. Lin WJ, Gary JD, Yang MC, Clarke S, Herschman HR. The mammalian immediate-
early TIS21 protein and the leukemia associated BTG1 protein interact with a protein 
arginine N-methyltransferase. J Biol Chem 1996;271:15034-15044. 
62. Singh V, Miranda TB, Jiang W, Frankel A, Roemer ME, Robb VA, Gutmann DH, 
Herschman HR, Clarke S, Newsham IF. DAL-1/4.1B tumor suppressor interacts with 
protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate 
substrates in vitro and in vivo. Oncogene 2004;23:7761-7771. 
  133 
63. Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase 
PRMT-1 and analysis of its binding to substrate peptides. Structure 2003;11:509-520. 
64. Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z. PRMT-1 and DDAHs-induced 
ADMA upregulation in involved in ROS and RAS mediated diabetic retinopathy. Exp 
Eye Res 2009;89:1028-1034. 
65. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear 
stress on asymmetric dimethylarginine release from vascular endothelial cells. 
Hypertension 2003;42:985-990. 
66. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, 
NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 
1989;264:10205-9. 
67. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by 
dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-1540. 
68. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide 
synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-
2575. 
69. Leiper JM, Murray-Rust J, McDonald N, et al. S-Nitrosylation of dimethylarginine 
dimethylaminohydrolase regulates enzyme activity: further interactions between nitric 
oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U 
S A 2002;99:13527-32. 
70. Jang J, Ho H-K, Kwan HH, et al. Angiogenesis is impaired by hypercholesterolemia: 
role of asymmetric dimethylarginine. Circulation 2000;102:1414-19. 
71. Kostourou V, Robinson SP, Cartwright JE, et al. Dimethylarginine 
dimethylaminohydrolase I promotes tumour growth and angiogenesis. Br J Cancer 
2002;87:673-80. 
  134 
72. Achan V, Tran CT, Arrigoni F, et al. All-trans-retinoic acid increases nitric oxide 
synthesis by endothelial cells: a role for the induction of dimethylarginine 
dimethylaminohydrolase. Cir Res 2002;90:764-9. 
73. Mehta S, Stewart DJ, Langleben D, et al. Short-term pulmonary vasodilation with L-
arginine in pulmonary hypertension. Circulation 1995;92:1539-45. 
74. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF receptor 
KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene 
expression by nitric oxide. J Clin Invest 1995;95:1798-1807. 
75. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, 
Wang X, Risau W, Ullrich A, Hirth P, McMahon G. SU5416 is a potent and selective 
inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits 
tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. 
Cancer Res 1999;59:99-106. 
76. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, 
Ellis LM, Weitman S, Shawver LK, Cherrington JM. Development of SU5416, a 
selective small molecule inhibitor of VEGF receptor tyrosinekinase activity, as an 
anti-antigen-esis agent. Anticancer Drug Design 2000;15:29-41. 
77. Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A. Pahse I 
dose escalating trial of SU5416, a novel angiogenesis inhibitor in patients with 
advanced malignancies. Proc Am Soc Clin Oncol 1999;18:618. 
78. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a 
phase I does –escalating study of the antiangiogenic agent, SU5416, in patients with 
advanced malignancies. Clin Cancer Res 2002;8:2798-2805. 
  135 
79. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Ke Cras TD, Abman SH, Hirth P, 
Waltenberger J, Voelkel NF. Inhibition of vascular endothelial growth factor receptors 
causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319. 
80. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR, 
Fontenot AP, Tuder RM, Voelkel NF. An animal model of autoimmune emphysema. 
Am J Respir Crit Care Med 2005;171:734-742. 
81. Kang K, Wagner PD, Breen EC. Lung-specific inactivation of VEGF in adult mice 
leads to emphysema like changes. Am J Respir Crit Care Med 2002;165:B54. 
82. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, 
Voelkel NF, Flores SC. Oxidative stress and apoptosis interact and cause 
emphysema due to vascular endothelial growth factor receptor blockade. Am J 
Respir Cell Mol Biol 2003;29:88-97. 
83. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, 
Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic 
hypoxia causes cell death dependent pulmonary EC proliferation and severe 
pulmonary hypertension. FASEB J 2001;15:427-438. 
84. Abe  K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka 
M. Formation of plexiform lesions in experimental severe pulmonary arterial 
hypertension. Circulation 2010;121:2747-2754. 
85. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Tosser R, Wilhelm J, Helmus 
K, Eul B, Zakrzewicz A, Ghofrani HA, Schermuly RT, Bohle RM, Grimminger F, 
Seeger W, Eickelberg O, Fink L, Weissmann N. Fhl-1, a new key protein in 
pulmonary hypertension. Circulation 2008;118:1183-1194. 
86. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, 
Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. 
  136 
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of 
pulmonary hypertension. Physiol Genomics 2008;33:278-291. 
87. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool 
C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased 
pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 
2007;175:1280-1289. 
88. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, 
Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in 
severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929. 
89. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A 
brady-kinin antagonist and a caspase inhibitor prevent severe pulmonary 
hypertension in a rat model. Can J Physiol Pharmacol 2002;80:269-274. 
90. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool 
CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. 
Expression of angiogenesis-related molecules in plexiform lesions in severe 
pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 
2001;195:367-374. 
91. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal 
endothelial cell proliferation is present in primary but not secondary pulmonary 
hypertension. J Clin Invest 1998;101:927-934. 
92. Yeager ME, Voelkel NF, Tuder RM. Mutational analysis of endothelial cell TGF-b 
receptor type II in plexiform lesions of patients with primary pulmonary hypertension. 
Circulation 1999;100:I-587. 
93. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia 
of the rat hilar pulmonary artery and their regression. Am J Pathol 1980;100:151-178. 
  137 
94. Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial 
fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997;150:1349-
1360. 
95. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic 
intervention in pulmonary hypertension. Pharmacol Ther 2001;92:1-20. 
96. Kakusaka I, Kabeko N, Kiyatake K, Fujita A, Suzuki A, Nakano K, Okada O, Sugita T, 
Watanabe S, Kuriyama T. Effects of various doses of monocrotaline administration 
on the development of pulmonary hypertension and its regression in rats. Nihon 
Hyobu Shikkan Gakkai Zasshi 1989;27:51-56. 
97. Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary 
arterial hypertension. Am J Respir Cell Mol Biol 2010;43:629-634. 
98. Nagasaka H, Okano Y, Aizawa M, et al. Altered metabolisms of mediators controlling 
vascular function and enhanced oxidative stress in asymptomatic children with 
congenital portosystemic venous shunt. Metabolism. 2010;59:107-13. 
99. Lu Z, Xu X, Hu X, et al. Oxidative stress regulates left ventricular PDE5 expression in 
the failing heart. Circulation. 2010;121:1474-83. 
100. Lu Z, Fassett J, Xu X, et al. Adenosine A3 receptor deficiency exerts unanticipated 
cardiac protective effects on the pressure overloaded induced ventricle hypertrophy. 
Circulation. 2008;118:1713-21. 
101. Xu X, Fassett J, Hu X, et al. Ecto-5’-nucleotidase deficiency exacerbates pressure-
overload-induced left ventricular hypertrophy and dysfunction. Hypertension. 
2008;51:1557-64. 
102. Xu D, Guo H, Xu X, et al. Exacerbated pulmonary arterial hypertension and right 
ventricular hypertrophy in animals with loss of function of extracellular superoxide 
dismutase. Hypertension. 2011;58:303-9. 
  138 
103. Handoko ML, de Man FS, Happe CM, et al. Opposite effects of training in rats with 
stable and progressive pulmonary hypertension. Circulation. 2009;120:42-49. 
104. Urboniene D, Haber I, Fang YH, Thenappan T, Archer DL. Validation of high-
resolution echocardiography and magnetic resonance imaging versus high-fidelity 
catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol 
Physiol. 2010;299:410-12. 
105. Mass R, Tan-Andreesen J, Schwedhelm E, Schulze F, Boger RH. A stable-isotope 
based technique for the determination of dimethylarginine dimethylaminohydrolase 
(DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci. 
2007;851:220-8. 
106. Lu Z, Xu X, Hu X, et al. PGC-1 alpha regulates expression of myocardial 
mitochondrial antioxidants and myocardial oxidative stress after chronic systolic 
overload. Antioxid Redox Signal. 2010;13:1011-22. 
107. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide 
synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. 
Circulation. 2004;109:500-5. 
108. Zhang P, Xu X, Hu X, Vandeel ED, Zhu G, Chen Y. Inducible nitric oxide synthase   
deficiency protects the heart from systolic overload-induced ventricular hypertrophy 
and congestive heart failure. Circ Res. 2007;100:1089-98. 
109. Machado RF, Londhe Nerkar MV, Dweik RA, Hammel J, Janocha A, Pyle J, 
Laskowski D, Jennings C, Arroliga AC, Erzurum SC. Nitric oxide and pulmonary 
arterial pressures in pulmonary hypertension. Free Radic Biol Med. 2004;37:1010-
1017. 
  139 
110. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial 
dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med.188:639-
646. 
111. Fagan KA, Fouty BW, Tyler RC, Morris KG, Jr., Hepler LK, Sato K, LeCras TD, 
Abman SH, Weinberger HD, Huang PL, McMurtry IF, Rodman DM. The pulmonary 
circulation of homozygous or heterozygous enos-null mice is hyperresponsive to mild 
hypoxia. J Clin Invest. 1999;103:291-299. 
112. Cooper CJ, Landzberg MJ, Anderson TJ, Charbonneau F, Creager MA, Ganz P, 
Selwyn AP. Role of nitric oxide in the local regulation of pulmonary vascular 
resistance in humans. Circulation. 1996;93:266-271. 
113. Radomski MW, Palmer RM, Moncada S. Characterization of the l-arginine:Nitric 
oxide pathway in human platelets. Br J Pharmacol. 1990;101:325-328. 
114. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of 
leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651-4655. 
115. Niu XF, Ibbotson G, Kubes P. A balance between nitric oxide and oxidants 
regulates mast cell-dependent neutrophil-endothelial cell interactions. Circ Res. 
1996;79:992-999. 
116. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, 
Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and 
molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 
2004;43:13S-24S. 
117. Michelakis ED. The role of the no axis and its therapeutic implications in pulmonary 
arterial hypertension. Heart Fail Rev. 2003;8:5-21. 
118. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary 
arterial hypertension. J Hypertens.28:201-212. 
  140 
119. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones 
PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, 
Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M. Inflammation, growth 
factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10-19. 
120. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, 
Choi JJ, Curtis E, Choi AM, Gladwin MT. Nitrite potently inhibits hypoxic and 
inflammatory pulmonary arterial hypertension and smooth muscle proliferation via 
xanthine oxidoreductase-dependent nitric oxide generation. Circulation. 2010;121:98-
109. 
121. Maruhashi T, Noma K, Iwamoto Y, Iwamoto A, Oda N, Kajikawa M, Matsumoto T, 
Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Liao JK, Higashi Y. Critical 
role of exogenous nitric oxide in rock activity in vascular smooth muscle cells. PLoS 
One.9:e109017. 
122. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total 
protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res. 
1995;76:305-309. 
123. Wells SM, Holian A. Asymmetric dimethylarginine induces oxidative and nitrosative 
stress in murine lung epithelial cells. Am J Respir Cell Mol Biol. 2007;36:520-528. 
124. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of 
enos-derived superoxide by endogenous methylarginines. Biochemistry. 
2008;47:7256-7263. 
125. Li XH, Peng J, Tan N, Wu WH, Li TT, Shi RZ, Li YJ. Involvement of asymmetric 
dimethylarginine and rho kinase in the vascular remodeling in monocrotaline-induced 
pulmonary hypertension. Vascul Pharmacol. 2010;53:223-229. 
  141 
126. Wells SM, Buford MC, Migliaccio CT, Holian A. Elevated asymmetric 
dimethylarginine alters lung function and induces collagen deposition in mice. Am J 
Respir Cell Mol Biol. 2009;40:179-188. 
127. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, 
Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial 
hypertension. Arterioscler Thromb Vasc Biol. 2005;25:1414-1418. 
128. Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, 
Settas L. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary 
arterial hypertension. Rheumatology (Oxford). 2008;47:1682-1685. 
129. Shao Z, Wang Z, Shrestha K, Thakur A, Borowski AG, Sweet W, Thomas JD, 
Moravec CS, Hazen SL, Tang WH. Pulmonary hypertension associated with 
advanced systolic heart failure: Dysregulated arginine metabolism and importance of 
compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol. 
2012;59:1150-1158. 
130. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical 
dimethyl-l-arginine in patients with congenital heart disease and pulmonary 
hypertension. J Cardiovasc Pharmacol. 2001;37:489-492. 
131. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, 
de Montellano PR, Kemp BE, Pearson RB. The akt kinase signals directly to 
endothelial nitric oxide synthase. Curr Biol. 1999;9:845-848. 
132. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-
Apte B, Erzurum SC. Hyperproliferative apoptosis-resistant endothelial cells in 
idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 
2007;293:L548-554. 
  142 
133. Tang H, Chen J, Fraidenburg DR, Song S, Sysol JR, Drennan AR, Offermanns S, 
Ye RD, Bonini MG, Minshall RD, Garcia JG, Machado RF, Makino A, Yuan JX. 
Deficiency of akt1, but not akt2, attenuates the development of pulmonary 
hypertension. Am J Physiol Lung Cell Mol Physiol. 2015;308:L208-220. 
134. Iannone L, Zhao L, Dubois O, Duluc L, Rhodes CJ, Wharton J, Wilkins MR, Leiper 
J, Wojciak-Stothard B. Mir-21/ddah1 pathway regulates pulmonary vascular 
responses to hypoxia. Biochem J. 2014;462:103-112. 
135. Bakr A, Pak O, Taye A, Hamada F, Hemeida R, Janssen W, Gierhardt M, Ghofrani 
HA, Seeger W, Grimminger F, Schermuly RT, Witzenrath M, Brandes RP, Huang N, 
Cooke JP, Weissmann N, Sommer N. Effects of dimethylarginine 
dimethylaminohydrolase-1 overexpression on the response of the pulmonary 
vasculature to hypoxia. Am J Respir Cell Mol Biol.49:491-500. 
136. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, 
Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic gmp 
phosphodiesterase 5a prevents and reverses cardiac hypertrophy. Nat Med. 
2005;11:214-222. 
137. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, 
Majmudar M, Gabrielson K, Halushka MK, Mitchell JB, Biswal S, Channon KM, Wolin 
MS, Alp NJ, Paolocci N, Champion HC, Kass DA. Reversal of cardiac hypertrophy 
and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling 
nitric oxide synthase as a therapeutic strategy. Circulation. 2008;117:2626-2636. 
138. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under 
pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary 
hypertension. Chest. 2009;135:794-804. 
 
  143 
139. Carling D, Thornton C, Woods A, Sanders MJ. Amp-activated protein kinase: New          
regulation, new roles? Biochem J. 2012;445:11-27. 
140. Hardie DG, Ross FA, Hawley SA. Ampk: A nutrient and energy sensor that 
maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-262. 
141. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, 
Nakamaru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa 
T, Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular 
smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ 
Res. 2005;97:837-844. 
142. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. Amp-
activated protein kinase inhibits angiotensin ii-stimulated vascular smooth muscle cell 
proliferation. Circulation. 2004;110:444-451. 
143. Zhang M, Dong Y, Xu J, Xie Z, Wu Y, Song P, Guzman M, Wu J, Zou MH. 
Thromboxane receptor activates the amp-activated protein kinase in vascular smooth 
muscle cells via hydrogen peroxide. Circ Res. 2008;102:328-337. 
144. Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, 
Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA. Mammalian target of 
rapamycin complex 2 (mtorc2) coordinates pulmonary artery smooth muscle cell 
metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation. 
2014;129:864-874. 
145. Song P, Zhou Y, Coughlan KA, Dai X, Xu H, Viollet B, Zou MH. Adenosine 
monophosphate-activated protein kinase-alpha2 deficiency promotes vascular 
smooth muscle cell migration via s-phase kinase-associated protein 2 upregulation 
and e-cadherin downregulation. Arterioscler Thromb Vasc Biol. 2013;33:2800-2809. 
  144 
146. Song P, Wang S, He C, Wang S, Liang B, Viollet B, Zou MH. Ampkalpha2 deletion 
exacerbates neointima formation by upregulating skp2 in vascular smooth muscle 
cells. Circ Res. 2011;109:1230-1239. 
147. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, 
Bache RJ, Chen Y. Amp activated protein kinase-alpha2 deficiency exacerbates 
pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. 
Hypertension. 2008;52:918-924. 
148. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura 
M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, 
Mochizuki N, Kitakaze M. Metformin prevents progression of heart failure in dogs: 
Role of amp-activated protein kinase. Circulation. 2009;119:2568-2577. 
149. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, 
Anaya-Cisneros M, Tian R, Lefer DJ. Activation of amp-activated protein kinase by 
metformin improves left ventricular function and survival in heart failure. Circ Res. 
2009;104:403-411. 
150. Xu X, Lu Z, Fassett J, Zhang P, Hu X, Liu X, Kwak D, Li J, Zhu G, Tao Y, Hou M, 
Wang H, Guo H, Viollet B, McFalls EO, Bache RJ, Chen Y. Metformin protects 
against systolic overload-induced heart failure independent of amp-activated protein 
kinase alpha2. Hypertension. 2014;63:723-728. 
151. Hu X, Xu X, Lu Z, Zhang P, Fassett J, Zhang Y, Xin Y, Hall JL, Viollet B, Bache RJ, 
Huang Y, Chen Y. Amp activated protein kinase-alpha2 regulates expression of 
estrogen-related receptor-alpha, a metabolic transcription factor related to heart 
failure development. Hypertension. 2012;58:696-703. 
  145 
152. Fassett JT, Hu X, Xu X, Lu Z, Zhang P, Chen Y, Bache RJ. Ampk attenuates 
microtubule proliferation in cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 
2013;304:H749-758. 
153. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner 
C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, 
Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The amp-activated 
protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin 
Invest. 2003;111:91-98. 
154. Chen Y, Guo H, Xu D, Xu X, Wang H, Hu X, Lu Z, Kwak D, Xu Y, Gunther R, Huo 
Y, Weir EK. Left ventricular failure produces profound lung remodeling and 
pulmonary hypertension in mice: Heart failure causes severe lung disease. 
Hypertension. 2012;59:1170-1178. 
155. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, 
Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine 
model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2011;184:1171-82. 
156. Lu Z, Xu X, Fassett J, Kwak D, Liu X, Hu X, Wang H, Guo H, Xu D, Yan S, McFalls 
EO, Lu F, Bache RJ, Chen Y. Loss of the eukaryotic initiation factor 2alpha kinase 
general control nonderepressible 2 protects mice from pressure overload-induced 
congestive heart failure without affecting ventricular hypertrophy. Hypertension. 
2014;63:128-135. 
157. Xu D, Guo H, Xu X, Lu Z, Fassett J, Hu X, Xu Y, Tang Q, Hu D, Somani A, Geurts 
AM, Ostertag E, Bache RJ, Weir EK, Chen Y. Exacerbated pulmonary arterial 
hypertension and right ventricular hypertrophy in animals with loss of function of 
extracellular superoxide dismutase. Hypertension. 2011;58:303-309. 
  146 
158. Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, 
Dubois-Rande JL, Amsellem V, Adnot S. Rapamycin reverses pulmonary artery 
smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol 
Biol. 2013;48:568-577. 
159. Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, 
Stenmark KR. Sustained hypoxia promotes the development of a pulmonary artery-
specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 
2009;297:L238-250. 
160. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, 
Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappab in 
human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26:611-617. 
161. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear 
factor kappab activation via amp-activated protein kinase activation in vascular 
endothelial cells. Hypertension. 2006;47:1183-1188. 
162. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, 
Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary 
vascular remodeling requires recruitment of circulating mesenchymal precursors of a 
monocyte/macrophage lineage. Am J Pathol. 2006;168:659-669. 
163. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Stenmark KR. Circulating 
mononuclear cells with a dual, macrophage-fibroblast phenotype contribute robustly 
to hypoxia-induced pulmonary adventitial remodeling. Chest. 2005;128:583S-584S. 
164. Bai J, Zhang N, Hua Y, Wang B, Ling L, Ferro A, Xu B. Metformin inhibits 
angiotensin ii-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS 
One. 2013;8:e72120. 
  147 
165. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y. Metformin 
attenuates cardiac fibrosis by inhibiting the tgfbeta1-smad3 signalling pathway. 
Cardiovasc Res. 2010;87:504-513. 
166. Huang X, Fan R, Lu Y, Yu C, Xu X, Zhang X, Liu P, Yan S, Chen C, Wang L. 
Regulatory effect of amp-activated protein kinase on pulmonary hypertension 
induced by chronic hypoxia in rats: In vivo and in vitro studies. Mol Biol Rep. 
2014;41:4031-4041. 
167. Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C, Savineau 
JP, Loirand G, Pacaud P. Protective role of the antidiabetic drug metformin against 
chronic experimental pulmonary hypertension. Br J Pharmacol. 2009;158:1285-1294. 
168. Fu X, Zhao JX, Zhu MJ, Foretz M, Viollet B, Dodson MV, Du M. Amp-activated 
protein kinase alpha1 but not alpha2 catalytic subunit potentiates myogenin 
expression and myogenesis. Mol Cell Biol. 2013;33:4517-4525. 
169. Crawford RM, Treharne KJ, Best OG, Riemen CE, Muimo R, Gruenert DC, Arnaud-
Dabernat S, Daniel JY, Mehta A. Ndpk-a (but not ndpk-b) and ampk alpha1 (but not 
ampk alpha2) bind the cystic fibrosis transmembrane conductance regulator in 
epithelial cell membranes. Cell Signal. 2006;18:1595-1603. 
170. Gusarova GA, Dada LA, Kelly AM, Brodie C, Witters LA, Chandel NS, Sznajder JI. 
Alpha1-amp-activated protein kinase regulates hypoxia-induced na,k-atpase 
endocytosis via direct phosphorylation of protein kinase c zeta. Mol Cell Biol. 
2009;29:3455-3464. 
 
 
